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Abstract
New technology is challenging conventional methods for characterizing pathogenic 
viruses in clinical laboratories. These newer methods are superior to older methods due to their 
ability to broadly target numerous pathogens in multiplexed ways. Even more intriguing, new 
technologies are capable of detecting viruses in non-targeted manners. Before these newer 
methods can be adopted by accredited medical laboratories, they must be validated to assess 
whether or not they meet minimum federal standards in terms of assay accuracy, precision, 
reproducibility, and cross-reactivity. This thesis begins to answer important questions facing 
clinical laboratories when adopting new technology. In Chapter 1, assays targeting single virus 
types are compared to a multiplexed assay using a proprietary electrochemical detection 
technology to determine if multiplexing has a detrimental effect on analytical sensitivity when 
detecting respiratory viruses simultaneously. Chapter 2 focuses on the issue of false positivity 
when testing for viruses in low-prevalence populations. To evaluate this, a multiplex flow 
immunoassay technology is used to perform surveillance of human immunodeficiency virus 
(HIV) infection in Alaskans, a low HIV-prevalence population. Chapter 3 describes clinical 
diagnostic applications of next-generation sequencing (NGS) providing examples of how NGS 
compares to conventional methods for characterizing pathogenic viruses such as hepatitis C 
virus, herpesvirus, adenovirus, and influenza virus. The final chapter describes how NGS can be 
used to characterize viruses by geographical region of transmission by analyzing an outbreak of 
canine parvovirus that occurred in the interior of Alaska. This chapter serves as a clear example 
of NGS's appeal to enhancing our epidemiological understanding during outbreaks. Although 
there are significant challenges to implementation, especially for NGS, each chapter shows 
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Clinical laboratories continually monitor the effectiveness of their assays to detect novel 
and variant pathogens and openly recognize the limitations of target-dependent testing. For this 
reason, new technologies for the diagnosis and monitoring of infectious pathogens are 
increasingly being utilized to account for the breadth of microbial diversity in clinical specimens 
[1]. Whole genome sequencing technology and its ability for broad characterization of all 
genetic information within a clinical specimen has helped enhance, as well as complicate, 
infectious disease analyses in the laboratory.
Commercial next-generation sequencing (NGS) platforms were launched in 2005 [2], a 
technology that has challenged the Sanger sequencing platforms which served as the gold 
standard for sequencing for over 30 years. In 2009, this newer sequencing technology was 
described in the literature as a potential tool not only for research, but for clinical diagnostics as 
well [3]. Now, nine years later, we are only beginning the validation processes necessary to bring 
sequence-based assays into the infectious disease clinical laboratory. The barriers preventing 
faster implementation include high start-up costs, confusion surrounding the clinical 
interpretation of results, lack of analysis pipelines (i.e. bioinformatics), and data storage [4]. 
This thesis contributes to the validation of assays utilizing new technology, including NGS, for 
the purposes of viral pathogen detection to address these issues.
Interpretation of sequencing data in clinical specimens is complicated by the large 
quantities of diverse genetic material contained in various matrices. For instance, trace amounts 
of pathogen nucleic acid can be found in clinical specimens but may not necessarily be 
attributable to the cause of disease. Although much research has been conducted describing the 
metagenomics of human biological materials, this has largely been centered on the prokaryotic 
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fraction of our microbiome [5]. In this thesis, clinical specimens derived from blood, skin 
swabs, the gastrointestinal tract, and the respiratory tract are evaluated for pathogenic viruses 
amongst the background of their metagenomes.
Viruses as a group lack a universal genetic biomarker, like bacteria's 16S ribosomal 
RNA, and have high mutation rates across small genomes making it difficult to design robust, 
long-lasting targeted assays [6]. The presence of known viral pathogens in different specimen 
matrices are briefly described in Table 0.1 to showcase the challenge of designing individual 
targeted tests for various human infections based on the sheer number of possible targets. 
Metagenomics is proven to be a powerful tool with endless areas of applications in virology, 
including the ability to identify novel or variant viruses in a target-independent manner [7]. 
However, using NGS for clinical diagnostics in virology can be complicated due to the presence 
of contaminating viruses in the testing environment and the human endogenous retroviruses 
within the human genome itself [8].
Federal regulations put in place to protect patients from receiving uninterpretable or 
inaccurate laboratory results require clinical laboratories to perform comprehensive validations 
to adopt assays that are not approved by the Federal Drug Administration (FDA). To comply 
with regulations, the performance of an assay must be documented and deemed acceptable by the 
clinical laboratory performing the test prior to releasing results to a patient. Acceptability is 
dependent upon specific parameters that must be established for each assay (Table 0.2). Since 
target-independent assays are capable of detecting novel viruses as well as potentially all 
variations, it is not feasible to validate all possible outcomes and therefore a combination of a 
“methods-based” and “analyte-specific” validation approach can be used [9, 10]. Despite 
2
challenges, validation protocols have been described for NGS assays [9, 11-14], and clinical 
applications are continuing to be described [15-17].
In this thesis, I compare conventional virus detection methods to those comprised of new 
technologies capable of broad pathogen detection. I also describe how data obtained by newer 
technologies can be applied to improving our overall epidemiological understanding of virus 
transmission during an outbreak scenario. Chapter 1 demonstrates a validation method in which 
to compare the analytical sensitivity of a new commercial electrochemical detection platform to 
commonly used real-time PCR assays for detecting large panels of respiratory viruses. Chapter 2 
evaluates the positive predictive value of a new HIV testing platform using multiplex flow 
immunoassay technology when performing surveillance in a population with low-HIV 
prevalence. Chapter 3 contrasts conventional virus detection strategies with NGS in terms of 
turnaround time and result comparability. The sequencing data obtained from the experiment 
described in chapter 3 reveals the true scarcity of targeted viral nucleic acid among the total 
nucleic acid captured from a clinical specimen. However, despite minimal representation in the 
specimen, clinically relevant information from targeted viral genomes pertaining to disease 
prophylaxis or treatment, such as the presence of antiviral resistance markers, is shown to be 
achieved in the initial non-targeted sequencing of a clinical specimen. Chapter 4 describes an 
outbreak investigation of canine parvovirus based on NGS data recovered from rectal swabs 
which describes how NGS data can be used to enhance our epidemiological understanding of 
disease transmission during an outbreak.
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Table 0.1: Known human viral pathogens classified by specimen origin used for detection
Specimen origin Viral pathogens of known clinical importance
GI tract (stool, rectal swabs) norovirus (3 genogroups), rotavirus (40 strains), enterovirus (>60 
serotypes, including polio) , hepatitis A & E virus, adenovirus (7 species, 
>50 types), sapovirus (4 genogroups), astrovirus (8 species), 
picobirnavirus, parechovirus (6 types), influenza (3 types), coronavirus (6 
types), torovirus [18, 19]
Blood (serum, plasma, buffy coat) Herpesviruses (8 types), anelloviruses (3 genera), parvovirus B19, human 
papillomavirus, adenovirus (7 species, >50 serotypes), HIV (2 types), 
human polyomavirus (11 types), hepatitis B virus, hepatitis C virus (6 
genotypes), influenza A (2 types) [20]
Respiratory tract (nasal swabs, 
pharyngeal swabs, sputum, aspirates, 
washes)
picornaviruses (rhinovirus (>100 serotypes), enterovirus (>60 serotypes), 
parechoviruses), paramyxoviruses (respiratory syncytial virus (2 groups), 
parainfluenzavirus (4 types), metapneumovirus, measles), influenza (3 
types), coronaviruses (4 types), adenovirus (5 serotypes), parvovirus, 
herpesvirus (4 species), anelloviruses (3 genera), papillomaviruses (>100 
types), polyomaviruses (11 types) [21]
Skin (rashes, lesions) Herpesviruses (8 types), Polyomavirus (11 types), Molluscum 
contagiosum, human papillomavirus (>100 types) [22-25]
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Table 0.2: Minimum parameters to establish acceptability of a new assay for human specimen 
testing
Parameter Protocol for targeted assays Adaptation for NGS (non-targeted)
Accuracy Test x number of specimens simultaneously using 
the gold standard method and the new assay. [26] 
Count the number of:
1) True Positives (TP): target is present on 
both assays
2) True Negatives (TN): target is absent on 
both assays
3) False Positive (FP): target is present on the 
new assay only
4) False Negative (FN): target is absent on the 
new assay only
Diagnostic Sensitivity = TP/(TP+FN)
Diagnostic Specificity = TN/(TN+FP) 
Positive Predictive Value = TP/(TP+FP) 
Negative Predictive Value = TN/(TN+FN)
Compare outcomes of NGS to those 
obtained by preferred (gold standard) 
methods, even if methodologies are 
different [27].
And
Compare the obtained sequences to the 
accepted reference sequence and evaluate 
depth of coverage (X), allelic read 
percentage, quality scores, and degree of 
coverage [11].
Precision Test the same positive and negative specimens 
repeatedly on the same run, on different runs, and by 
different people.
Intra-assay precision: Calculate coefficient of 
variability of values obtained from duplicates on the 
same run
Inter-assay precision: Calculate coefficient of 
variability of values obtained from duplicates on 
different runs [28]
Prepare a specimen in duplicate for testing 
on the target-independent system. Have a 
different person repeat the duplicates on a 
different day. [11, 12]
Reportable
Range
Report the span of test result values for which the 
test system is accurate [29]
Define the portion of the genome for which 




Define the range of test values expected for the 
normal healthy population [29]
Normal variation of the sequence of interest 
within the population that the assay is 
designed to test. [11]
Analytical
Sensitivity
Perform replicates of multiple dilutions of a 
specimen with known analyte quantity to determine 
the lowest reliably detectable concentration. Also 
called the limit of detection (LOD). [30]
Perform replicates of specimens containing 
known disease-causing variants, calculate 
the average FN rate [11, 12]
Analytical
Specificity
Spike specimens with genetically similar organisms 
and specimen-related interfering substances 
(hemolysis, lipemia, medications, etc.) to determine 
cross-reactivity [30]
Perform replicates of specimens not 
containing known disease-causing variants, 
calculate the average FP rate [12]
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Chapter 1 Analytical sensitivity comparison between singleplex real-time PCR and a multiplex
PCR platform for detecting respiratory viruses1
1 Parker, J., N. Fowler, M. L. Walmsley, T. Schmidt, J. Scharrer, J. Kowaleski, T. Grimes, S. Hoyos and J. Chen. 
Analytical Sensitivity Comparison between Singleplex Real-Time PCR and a Multiplex PCR Platform for Detecting 
Respiratory Viruses. PLOS ONE, 2015. 10(11): e0143164. In this chapter, data was reanalyzed and some of the of 
the writing was modified to reflect these changes. The original publication can be found in Appendix A.
1.1 Abstract
Multiplex polymerase chain reaction (PCR) methods are attractive to clinical laboratories 
wanting to broaden their detection of respiratory viral pathogens in clinical specimens. However, 
multiplexed assays must be well optimized to retain or improve upon the analytic sensitivity of 
their singleplex counterparts. In this experiment, the lower limit of detection (LOD) of singleplex 
real-time PCR assays targeting respiratory viruses is compared to an equivalent panel on a 
multiplex PCR platform, the GenMark eSensor respiratory virus panel (RVP). LODs were 
measured for each singleplex real-time PCR assay and expressed as the lowest copy number 
detected 95-100% of the time, depending on the assay. The GenMark eSensor RVP LODs were 
obtained by converting the TCID50/mL concentrations reported in the package insert to copies 
number equivalents using quantitative PCR (qPCR). LOD differences between the two methods 
ranged from 3 to 6,759 copies (0.46- 3.83 log difference) for all 12 assays compared. Assays 
targeting human parainfluenza 1 and 2 were most comparable (3 to 6 copies, < 1 log difference). 
Largest differences in LOD were demonstrated for assays targeting adenovirus group E, 
respiratory syncytial virus subtype A, and a generic assay for all influenza A viruses regardless 
of subtype (1,929 - 6,732 copies, 3.28-3.83 log difference). The multiplex PCR platform, the
9
GenMark eSensor RVP, had better analytical sensitivity for detecting influenza A/H3 viruses, 
influenza B virus, and human rhinovirus with estimated detection improvement by 28 - 510 
copies (1.45 to 2.70 logs). Broader detection of influenza A/H3 viruses was demonstrated by the 
GenMark eSensor RVP. The relationship between TCID50/mL concentrations and the 
corresponding copy number related to various ATCC cultures is also reported.
1.2 Introduction
Multiplex PCR methods, those that target more than one pathogen in a single test, benefit 
diagnostics in a clinical laboratory due to their ability to detect and rule-out many related 
pathogens in the same amount of time. New and improved workflow designs make it possible for 
laboratories with varied molecular technical ability to implement multiplex PCR platforms.
The Respiratory Viral Panel (RVP) manufactured by GenMark Diagnostics, Inc. is a 
multiplex PCR panel that detects the amplification of various viral gene fragments 
electrochemically. Nucleic acids from targeted viral pathogens are amplified using a multiplex 
PCR reaction followed by denaturation of the double stranded molecules into single 
oligonucleotide strands using exonuclease. Once the amplicons are in a single-stranded state, 
they are hybridized to a complementary virus-specific signal probe tagged with ferrocene, a 
reducing agent. This hybridized molecule is then exposed to another sequence-specific probe 
which is bound to a solid phase, a gold electrode. Upon application of a low voltage current, the 
hybridized molecule bound to this solid phase brings the ferrocene in close proximity to the gold 
electrode where reversible electron transfer can occur and the resulting current can be measured. 
Viral pathogenic nucleic acid can be detected with confidence when measurements are > 3 
nanoamps (nA) on the GenMark XT-8 instrument. The GenMark eSensor RVP has been shown 
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to be highly comparable to other multiplex PCR platforms as well as singleplex real-time PCR in 
terms of diagnostic sensitivity and specificity [1, 2]. In this chapter, the primary interest is the 
analytical sensitivity of the PCR assays, or the minimum detectable concentration of the target. 
The GenMark eSensor RVP LODs as determined by the manufacturer are compared to 
singleplex real-time PCR assay LODs determined by our laboratory and expressed as the lowest 
copy number reliably detected 95-100% of the time.
Limit of detections for FDA-approved clinical assays, including those described in the 
GenMark eSensor RVP package insert, are commonly expressed as 50% tissue culture infectious 
dose per milliliter, or TCID50/mL. Although this is a standard practice, other quantification 
methods such as real-time PCR are also reliable and may be able to more precisely describe 
quantities of viral particles with or without TCID50/mL calculations as a reference [3-6]. Since 
the LODs for the GenMark RVP assays are expressed exclusively as TCID50/mL concentrations, 
these values needed to be converted to copy number equivalents in order to meet our goals of 
comparing analytical sensitivity as lowest copy number. The LODs of each GenMark RVP assay 
were not re-established in our laboratory. Instead, manufacturer established TCID50/mL values 
were converted to copy number using quantitative real-time PCR (qPCR). Performing this 
conversion also provided an opportunity to view the relationship between TCID50/mL and copy 
number and relate this information to various virus-infected ATCC cell cultures.
The respiratory assays evaluated in this experiment target the following virus species:
influenza A virus/H3, influenza A/H1N1, influenza B virus, human respiratory syncytial virus
(RSV), human parainfluenza virus (serotypes 1, 2, and 3), human adenovirus, and human
rhinovirus. The multiplex GenMark eSensor RVP assays were able to further distinguish human
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adenoviruses as belonging to subgenera C or E and respiratory syncytial viruses as belonging to 
subgroup A or B, unlike the singleplex real-time PCR assays that were designed to detect human 
adenovirus and respiratory syncytial virus universally across all subgroups. A generic influenza 
A virus assay, one that targets a conserved region of all influenza A viruses regardless of 
subtype, was also evaluated.
1.3 Methods and Materials
1.3.1 Clinical specimens
Clinical specimens used in this study were de-identified. The University of Alaska 
Fairbanks Institutional Review Board (IRB) has determined that the proposed research 
qualifies for exemption from the requirements of 45 CFR 46 (Approval number: 667418­
1).
1.3.2 Preparation of standard materials
Specific plasmids were created for each real-time PCR assay by ligating single 
copies of the diagnostic amplicon onto vectors (pCR 2.1 or pCR4, Invitrogen) and 
amplifying via TOPO cloning (Invitrogen). Transformant E.coli competent cells were 
extracted using a phenol/chloroform mixture and the presence of viral-specific inserts 
was verified by sequencing (Elim Biopharmaceuticals, Inc.).
Eleven plasmids were constructed and quantified using a gel electrophoresis 
method to exclude contaminating fragments of unwanted size as well as verify plasmid 
quality in terms of degradation. Due to their circular and supercoiled nature, the plasmids 
were linearized with restriction enzymes (either NcoI or SphI) to normalize their 
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movement through the gel matrix. An in-house standard was created from a plasmid of 
similar length (size ~4KB) as a comparator for plasmids of unknown quantity. A portion 
of the in-house standard was quantified using a fluorometer specific for DNA (Qubit 2.0) 
prior to running each gel, diluted, and added to wells as a standard curve. Using ImageJ 
software, a measurement tool with fixed area assigned values associated with pixel 
intensity of the fluorescing gel bands [7]. In addition to measuring the pixel intensity of 
each band, the intensity of a background image was also taken and subtracted from the 
initial measurement. The mass (in nanogram, ng) of the in-house standard was plotted 
against measured pixel intensities and a logarithmic trend line was used to interpolate the 
pixel intensity of the unknown plasmids and estimate their quantities in ng. Once mass 
was established for each gel band, the volume added to the gel was considered and a 
dilution factor was assigned based on the volume of stock plasmid represented in the 
restriction enzyme digests (total volume 25μL) to determine concentrations (ng/copy).
The weight of each plasmid was calculated using Geneious (v.8.1.3) by taking into 
account the known sequence of the vector in addition to the Sanger-confirmed sequence 
of the insert. Final copy numbers concentrations (copies∕μL) were calculated by dividing 
the plasmid weights (ng/copy) into the plasmid concentrations (ng∕μL). Results of the 
quantification methods and downstream calculations are shown in Table 1.1 and 
Appendix 1.A.
1.3.3 Determination of singleplex real-time LOD
Stock plasmids were serially diluted to test a range of concentrations. Two 
identical dilution series were prepared, 1) diluted plasmids with nuclease-free water as 
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diluent and 2) diluted plasmids using pooled clinical specimen eluates (absent of the 
target) to simulate a clinical matrix. A narrow range of concentrations were chosen to 
identify the lowest potential copy number able to be detected repeatedly, but keep it 
above theoretical limitations of real time PCR, <3 copies (0.6 copies∕μL when using 5μL 
reactions) [8]. Replicates (n=7) of each dilution were tested to determine the assay's 
LOD. Negative controls consisted of no template control replicates (NTC, n = 3) and 
diluent blank replicates, made up of water or patient eluate diluent (n = 7) to assess 
contamination. Positive reactions were defined as those amplification curves that 
produced cycle threshold (Ct) values at or below 40 cycles.
Primers and probes used in the laboratory-developed real-time PCR assays have 
been previously described [9, 10]. Influenza assays were performed using Invitrogen 
Superscript III reagents and all other assays were performed using Ambion AgPath ID 
reagents. For assays using the Invitrogen reagents, the following PCR thermal cycling 
profile was used; 50°C hold for 30 minutes, 95°C hold for 2 minutes, and 45 cycles of 
95°C for 15 seconds then 55°C for 30 seconds. For assays using the Ambion reagents, 
the following PCR thermal cycling profile was used; 45°C hold for 10 minutes, 95°C for 
10 minutes, and 45 cycles of 95°C for 15 seconds then 55°C for 1 minute. Reactions 
were tested using ABI 7500Dx thermal cyclers (Life Technologies).
The goal of these experiments was to determine the lowest copy number 
detectable by the assay 95-100% of the time, depending on the assay, to match the 
degree of positivity reported for the comparator GenMark assays. Most assays' LODs 
were set at 100% positivity, but three assays (influenza A/H1N1, RSVA, and 
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rhinovirus) were set lower and required further analysis to determine comparable 
LODs. This was done using probability units (probits) which are commonly used to 
show drug dose responses but can be used similarly for LOD determinations to evaluate 
assay performance (response) when provided various concentrations of DNA template 
(dose) [11]. Final LODs were expressed as copies per 5μL, the volume of template 
requred for each reaction (Table 1.2, Appendix 1.B).
1.3.4 Conversion of TCID50/mL concentrations to copy number
Cell cultures with known TCID50/mL quantities of target viruses (ATCC) were 
used to estimate the LOD for the GenMark RVP assay. Cultures were stored in liquid 
nitrogen until they were extracted using the easyMAG total nucleic acid automated 
extractor (Biomerieux). A total of 200μL of the TCID50∕mL culture was extracted and 
final eluate volumes were 60μL. Purified nucleic acid was stored at -80°C until tested by 
quantitative real-time PCR (qPCR).
Ten-fold dilutions of quantified plasmids containing inserts specific to each assay 
were tested in triplicate to create a standard curve (Appendix 1.C). All qPCR assays 
utilized a sequence-specific hydrolysis probe with the exception of the influenza A/H3 
assay due to sequence incompatibilities with the ATCC strain being analyzed (see 
results). In this case, a SYBR Green assay (GoTaq, Promega) with new primers were 
designed to target this specific strain of influenza A/H3. Alongside the standard curve, 
dilutions of the isolated nucleic acid derived from the ATCC cultures were tested in 
triplicate at dilutions that would include reported GenMark eSensor RVP LOD 
TCID50/mL values. As with the singleplex real-time PCR assays, reactions were tested
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on ABI 7500Dx thermal cyclers (Life Technologies) and standard curves and associated 
unknown quantities were analyzed using ABI 7500 v2.3 software. The copy number 
equivalents for each GenMark eSensor assay's LOD is shown in Table 1.2. The 
relationship between copy number and TCID50/mL for each ATCC culture tested is 
shown in Table 1.3.
1.4 Results
The analytical sensitivities of ten singleplex real-time PCR assays were compared to 
twelve multiplexed PCR GenMark eSensor RVP assays. The real-time PCR assays could not 
distinguish between different groups of adenovirus and respiratory syncytial viruses (RSV), 
while the GenMark eSensor RVP assay differentiates adenovirus group C vs. E and RSVA vs. 
RSVB, thus two more assays were evaluated for the GenMark eSensor RVP. Analytical 
sensitivity was expressed as lowest copy number for all assays.
Two of the twelve assays assessed, human parainfluenza 1 and 2, demonstrated similar 
performance between methods (<1 log copy number difference, Table 1.2). Three assays 
compared showed improved sensitivity using the multiplexed GenMark platform. These 
include the influenza A/H3, influenza B, and human rhinovirus assays which proved to have 
LODs exceeding that of the qPCR assay. Copy numbers reported for these assays are 
considered estimates since they were derived from continuing trend lines beyond the qPCR 
LOD. The GenMark eSensor human rhinovirus assay demonstrated the biggest difference in 
terms of improved detection when compared to its singleplex counterpart (estimated 510 ± 89 
copies, 2.70 ± 0.1 log difference). Seven of the twelve assays compared showed greater 
sensitivity using the real-time singleplex assays. These include the adenovirus assays (C & E), 
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influenza A (generic), influenza A/H1N1, human parainfluenza 3, and RSV (A & B) with 
improvement ranging from 580 to 6,732 copies (2.75 to 3.83 log differences).
The Genmark eSensor RVP capable of distinguishing between different subgenera of 
adenoviruses (C vs. E) demonstrated less analytical sensitivity than the generic singleplex real­
time PCR assay targeting all adenoviruses, differing by 1,033 ± 435 copies (2.99 ± 0.2 log 
difference), and 2,941 ± 379 copies (3.47 ± 0.6 log difference), respectively. The difference in 
sensitivity may be due to slight variations in the targeted priming region. The singleplex real­
time PCR assays use primers designed to anneal highly conserved sequences within the hexon- 
coding region in order to target all adenoviruses, whereas the GenMark eSensor assays use 
subgenera-specific hexon primers to make the distinction between adenovirus group C and E 
possible. In terms of surveillance, differentiation of virus subtypes within a population may be 
important, regardless of lost sensitivity. Upper respiratory tract infections associated with 
adenovirus C viruses infect more than 80% of the population early in life [12]; however, 
infections with the adenovirus E serotype (type 4) can prove to be more severe and even fatal 
for people living in close quarters, such as military recruits [13]. In terms of surveillance, 
differentiation of virus subgenera within a population may be clinically useful, regardless of lost 
sensitivity.
Similarly, the singleplex real-time assay generically targeting RSV also demonstrated
better sensitivity than the GenMark eSensor assays which are capable of distinguishing subtypes
A and B (1,929 ± 154 copies, 3.28 ± 0.04 log difference and 580 ± 47 copies, 2.76 ± 0.04 log
difference, respectively). Respiratory syncytial viruses in subtype A are thought to be more
prevalent and virulent than those in subtype B [14]. Despite lower sensitivity, subtyping
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respiratory syncytial virus may be beneficial when surveilling populations that experience high 
hospitalization rates associated with RSV, such as Native Americans living in southwest United 
States and Alaska [15].
Human parainfluenza 1 and 2 assays were highly comparable (6 ± 4 copies, 0.68 ± 0.3 
log difference and 3 ± 2 copies, 0.46 ± 0.3 log difference, respectively). Human parainfluenza 3 
assays demonstrated the largest difference in analytical sensitivity among the human 
parainfluenza serotypes, demonstrating a 2.86 ± 0.1 log improvement in detectability when 
using the singleplex real-time PCR assay (725 ± 101 copy difference).
Analytical sensitivity of assays targeting the current circulating strains of influenza A 
viruses in the human population, influenza A/H3 and influenza A/H1N1, demonstrated variable 
sensitivity between assays (76 ± 2 copies, 1.88 ± 0.01 log difference and 580 ± 149 copies, 
2.75 ± 0.1 log difference, respectively), with the GenMark influenza A/H3 assay outperforming 
the singleplex assay in terms of sensitivity. Comparing the LOD between the influenza H3N2 
assays proved to be the most challenging. When converting TCID50/mL concentrations to copy 
numbers using qPCR, it was determined that this particular culture contained an uncommon 
virus, an Aichi strain (A/Aichi/2/35) circa 1968 (ATCC) and therefore could not be amplified 
using the singleplex real-time PCR assay, which is designed to detect current influenza A/H3N2 
virus strains. However, it was repeatedly detected using the GenMark eSensor RVP. This 
finding suggests that the eSensor RVP is capable of detecting a broader range of influenza 
A/H3N2 strains while improving upon the analytic sensitivity of its singleplex real-time PCR 
counterpart.
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The greatest difference measured between analytic sensitivities was seen with the generic 
influenza A assay showing a 3.83 ± 0.5 log difference in LOD (6,732 ± 843 copy difference) 
confirming better sensitivity with the singleplex assay. Because the LOD for the generic 
influenza A assay is much higher than the subtype assays (as described above) for the multiplex 
GenMark eSensor RVP, difficulty in result interpretation from specimens with low influenza A 
virus titers is likely (e.g. non-reactive influenza A (generic) reaction paired with a reactive 
H3N2 reaction). The performance of the generic influenza A assay is an important surveillance 
tool for tracking genetic changes among influenza A viruses. For instance, specimens 
demonstrating positivity for influenza A using this generic, highly conserved matrix-coding 
region may not subtype using the influenza A/H3 or influenza A/H1N1 assays, which may 
indicate that the virus is novel and worthy of alerting public health authorities. Therefore, it is 
imperitive for surveillance programs to use highly sensitive generic influenza A assays. In 
contrast, the influenza B assays were shown to be highly comparable between the singleplex 
and multiplex assays, with a difference of only 28 ± 3 copies (1.45 ± 0.1 log difference), 
showing slightly better sensitivity on the GenMark RVP assay.
The number of genome copies per TCID50/mL value was highly variable ranging from 
0.003 ± 0.0013 to 4,430 ± 56,329 (Table 1.3). LODs set at higher TCID50/mL concentrations 
(103) corresponded to stock cultures with lower copy numbers (0.003 ± 0.0013 copies per 
TCID50). LODs set at in the mid-range TCID50/mL concentrations (101 to 10-1) corresponded to 
stock cultures with variable copy numbers per TCID50/mL (10 ± 1 to 5,686 ± 1,419 copies). 
LODs set at lower TCID50/mL concentrations (10-2 to 10-3) corresponded to stock cultures with 
higher copy numbers per TCID50/ mL (391 ± 142 to 56,329 copies).
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1.5 Conclusion
Multiplex PCR applications benefit diagnostics in a clinical laboratory due to their ability 
to detect and rule-out many related pathogens in a single reaction, reducing technician time by 
more than 3 hours for a panel of 10 viruses [1]. However, multiplex PCR platforms continue to 
struggle with loss in sensitivity. Analytic sensitivity, or the lowest possible concentration 
necessary to produce a reliable result, is an important parameter to consider when replacing 
singleplex realtime PCR assays with multiplex PCR platforms evolving from newer, more 
expensive technologies. This experiment aims at finding a method in which to compare LODs of 
various assays using copy number as the unit of expression.
Choosing a 2.5 log difference to express considerable loss in sensitivity, the multiplex 
PCR strategy in combination with the GenMark eSensor technology demonstrated a considerable 
loss in sensitivity for seven of the twelve assays assessed. Four of the assays were adenovirus 
groups C and E and respiratory syncytial virus subtypes A and B. Although sensitivity is 
reduced, further characterization of viruses in clinical specimens may be of greater clinical 
importance, especially when particular subtypes are known to be more virulent in the population 
as is the case with adenovirus serotype 4 (subgenera E) and respiratory syncytial virus subtype A 
in particular populations. The parainfluenza 3 assay also demonstrated loss in sensitivity, but 
showed it can be multiplexed without reducing the sensitivity of the parainfluenza serotypes 1 
and 2 assays.
Two assays demonstrating considerable loss in sensitivity was the generic influenza A 
assay and, to a lesser extent, the influenza A/H1N1 assay. Clinical laboratories, especially those 
directly related to public health surveillance, may need to consider the significance of this 
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reduced sensitivity since it is commonly used to rule out novel influenza. Better analytic 
sensitivity was achieved using singleplex real-time PCR, which indicates that influenza A can be 
detected in clinical specimens even at low titers using this method. Specimens collected from 
patients that are suspected to have influenza infections that test negative on the GenMark 
eSensor RVP may need to be tested by more sensitive methods to rule out cases of novel 
influenza.
Expressing LOD in units that can be comparable across methodologies can prove to be 
difficult experimentally. TCID50/mL measurements can vary depending on how these cultures 
are handled in the laboratory in regards to preserving the concentration of infectious virus 
particles for purposes of experimentation and quantity comparisons. Molecular detection 
strategies used in clinical laboratories are non-discriminating when identifying nucleic acid. PCR 
methodologies used to detect viral targets in clinical specimens cannot determine the viability of 
the virus and, therefore, every detection may not point to a causative agent of disease. Other 
complicating factors to consider when interpreting PCR results are that patients can be 
asymptomatic carriers or may be exhibiting evidence of a past infections. Viral copy numbers 
provide an estimate of the number of virus particles in a given volume, but in our experiment, 
they did not correlate well with the number of infectious particles. To test the analytical 
sensitivity of a PCR-based methodology, it is important to understand that the intent of the assay 
is to detect any genome copy targeted by the designed primers, whether these be from infectious 
or non-infectious virus particles.
21
1.6 Acknowledgments
This research was supported by the Alaska Department of Health and Social Services, 
Division of Public Health, Section of laboratories. Much of the plasmid development and 
sequencing was supported in part by the University of Alaska Fairbanks. The ATCC cultures 
were purchased by GenMark Diagnostics, Incorporated in an effort to be consistent with the 
particular strains used in the FDA validation testing. We would like to thank the staff at the 
Alaska State Virology Laboratory for all of their help with carrying out testing for this project.
22
Table 1.1: Plasmid concentrations and copy number determination












Adenovirus pCR2.1 48.9 4.17 x 10-9 1.17 x 1010 7.5 1.80 x 109
Influenza A (generic) pCR2.1 23.5 4.14 x 10-9 5.68 x 109 10 2.41 x 109
Influenza A∕H3 pCR4 9.4 4.37 x 10-9 3.02 x 109 7.5 1.72 x 109
Influenza A∕H1N1 pCR2.1 10.8 4.15 x 10-9 2.60 x 109 10 2.41 x 109
Influenza B pCR4 38.1 4.17 x 10-9 9.14 x 109 25 6.00 x 109
Parainfluenza 1 pCR4 72.0 4.32 x 10-9 1.67 x 1010 10 2.31 x 109
Parainfluenza 2 pCR4 103.6 4.15 x 10-9 2.50 x 1010 5 1.20 x 109
Parainfluenza 3 pCR4 31.6 4.19 x 10-9 7.54 x 109 5 1.19 x 109
RSVA pCR4 48.5 4.28 x 10-9 1.13 x 1010 10 2.34 x 109
RSVB pCR4 9.3 4.28 x 10-9 2.17 X 109 5 1.17 x 109
Rhinovirus pCR4 44.4 4.27 x 10-9 1.04 x 1010 30 7.02 x 109
RSV = respiratory syncytial virus. Weight per copy was calculated using Geneious (v.8.1.3) which considers the 
exact sequence of the plasmid, including the specific virus target insertion. See Appendix 1.A describing calculations. 
This table has been updated since the original publication which can be found in Appendix A.
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Similar assay performance ( < 1 log difference)
Parainfluenza 1 100% 5 5 11 ± 4 6 ± 4 0.68 ± 0.3
Parainfluenza 2 100% 27 11 28 ± 4 3 ± 2 0.46 ± 0.3
GenMark RVP assays with better sensitivity
Influenza A/H3 100% 80 40 4 ± 2 (est.) 76 ± 2 1.88 ± 0.01
Influenza B 100% 33 660 5 ± 3 (est.) 28 ± 3 1.45 ± 0.1
Rhinovirus 97.5% 517 263 7 ± 89 (est.) 510 ± 89 2.70 ± 0.1
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Singleplex real-time PCR assays with better sensitivity
Adenovirus C 100% 8 20 1,041 ± 435 1,033 ± 435 2.99 ± 0.2
Adenovirus E 100% 8 20 2,948 ± 379 2,941 ± 379 3.47 ± 0.6
Influenza A (generic) 100% 27 106 6,759 ± 843 6,732 ± 843 3.83 ± 0.5
Influenza A/H1N1 95% 34 34 597 ± 149 580 ± 149 2.75 ± 0.1
Parainfluenza 3 100% 11 5 736 ± 101 725 ± 101 2.86 ± 0.1
RSVA 97.5% 27 10 1,952 ± 188 1,929 ± 154 3.28 ± 0.04
RSVB 100% 11 26 591 ± 47 580 ± 47 2.76 ± 0.04
Lowest copy numbers are expressed as the nearest whole number of copies in 5μL of eluate used in each reaction.
Adenovirus assays were not differentiated with the singleplex real-time PCR assay. The TCID50/mL concentration for 
influenza A/H3, influenza B, and rhinovirus exceeded the detection limit of the qPCR assay and are considered estimates 
(est.) of continued trend lines beyond the qPCR LOD. Copy number differences were calculated using the singleplex LODs 
in clinical background in comparison to the average copy number equivalent of the GenMark RVP LODs. See Appendix 1.B 
for singleplex assay calculation details and Appendix 1.C describing TCID conversions to copy numbers. This table has been 
updated since the original publication which can be found in Appendix A.
Table 1.3: Relationship between TCID50/mL concentrations and copy number
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ATCC Culture







VR-1 Adenovirus Type 1 (C) 8.89 x 101 1,041 ± 435 12 ± 5
VR-1572 Adenovirus Type 4 (E) 1.58 x 101 2,948 ± 379 187 ± 24
VR-547 Influenza A∕H3 (Aichi) 1.58 x 103 4 ± 2 0.003 ± 0.0013
VR-1736 Influenza A/H1N1 1.05 x 10-1 597±149 5,686 ± 1,419
VR-101 Influenza B 3.16 x 10-1 5 ± 3 16 ± 9
VR-94 Human Parainfluenza Virus Type 1 (C35) 2.81 x 10-2 11 ± 4 391±142
VR-92 Human Parainfluenza Virus Type 2 (Greer) 2.81 x 100 28 ± 4 10 ± 1
VR-93 Human Parainfluenza Virus Type 3 (C243) 2.81 x 101 736±101 26 ± 4
VR-1540 Respiratory Syncytial Virus (A2) 2.81 x 100 1,952 ± 188 695 ± 67
VR-955 Respiratory Syncytial Virus (B9320) 1.58 x 100 591 ± 47 374 ± 30
VR-483 Rhinovirus 3 FEB 1.58 x 10-3 7 ± 89 4,430 ± 56,329
Using the equivalent copy number determination at the LOD TCID50/mL concentration for each assay, the number of 
copies per TCID50/mL designation is estimated with standard error. This table has been updated since the original 
publication which can be found in Appendix A.
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Plasmid construction and quantification details
This appendix describes the laboratory details of constructing eleven plasmids containing 
inserts from respiratory viruses and how they were quantified. Once original concentrations 
were assigned for each plasmid, stock solutions were prepared for use in the LOD experiments 
(Appendix 1.B and 1.C). In the following figures, gel images show mass in nanograms over 
each gel band for the standard curve and the amount estimated for each individual respiratory 
virus plasmid. Tables below each gel image list pixel intensity measurements for each band 
alongside a logarithmic plot used to determine unknown plasmid quantities based on the pixel 
intensity of gel band images. Final concentrations and corresponding copy numbers are listed at 
the bottom.
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Figure 1.A-1: Adenovirus (Ad2-4) plasmid details. Plasmid was linearized using restriction 
enzyme NcoI.
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Figure 1.A-2: Influenza A (FluA-7) plasmid details. Plasmid was linearized using restriction 
enzyme NcoI.
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Figure 1.A-3: Influenza A/H3 (H3-4-49) plasmid details. Plasmid was linearized using 
restriction enzyme NcoI.
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Figure 1.A-4: Influenza A/H1N1 (pdmH1-40) plasmid details. Plasmid was linearized using 
restriction enzyme NcoI.
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Figure 1.A-5: Influenza B (FluB-6) plasmid details. Plasmid was linearized using restriction 
enzyme NcoI.
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Figure 1.A-6: Parainfluenza 1 (Para1-22) plasmid details. Plasmid was linearized using 
restriction enzyme NcoI.
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Figure 1.A-7: Parainfluenza 2 (Para2-12) plasmid details. Plasmid was linearized using 
restriction enzyme SphI.
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Figure 1.A-8: Parainfluenza 3 (Para3-3) plasmid details. Plasmid was linearized using restriction 
enzyme NcoI.
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Figure 1.A-9: Respiratory syncytial virus A (RSVA-1) plasmid details. Plasmid was linearized 
using restriction enzyme SphI.
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Figure 1.A-10: Respiratory syncytial virus B (RSVB-3) plasmid details. Plasmid was linearized 
using restriction enzyme NcoI.
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Establishing limits of detection for singleplex real-time PCR assays
Plasmids described in Appendix 1.A were used to determine the limit of detection (LOD) 
of ten singleplex real-time PCR assays targeting human respiratory viruses. Two separate RSV 
plasmids were created (RSVA and RSVB) and tested on the same real-time PCR assay. This 
appendix describes the laboratory details of each LOD experiment. In the following figures, 
positive reactions are depicted as black circles and negative reactions are shown as empty circles. 
The percentage of reactions that are positive for each dilution is shown below each column. 
Three assays underwent probit analysis for LODs set at positivity levels less <100%, influenza 
A/H1N1 (95%), RSVA (97.5%), and human rhinovirus (97.5%).
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Figure 1.B-1: Adenovirus singleplex real-time PCR assay limit of detection determination
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Figure 1.B-2: Influenza A (generic) singleplex real-time PCR assay limit of detection 
determination
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Figure 1.B-3: Influenza A/H3 singleplex real-time PCR assay limit of detection determination
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Figure 1.B-4: Influenza A/H1N1 singleplex real-time PCR assay limit of detection determination 
using probit values
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Figure 1.B-5: Influenza B singleplex real-time PCR assay limit of detection determination
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Figure 1.B-6: Parainfluenza 1 singleplex real-time PCR assay limit of detection determination
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Figure 1.B-7: Parainfluenza 2 singleplex real-time PCR assay limit of detection determination
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Figure 1.B-8: Parainfluenza 3 singleplex real-time PCR assay limit of detection determination
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Figure 1.B-9: RSVA singleplex real-time PCR assay limit of detection determination using 
probit values
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Figure 1.B-10: RSVB singleplex real-time PCR assay limit of detection determination
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Converting TCID dilutions to copy number equivalents
The purpose of this appendix is to show the laboratory methods used to convert tissue 
culture infectious dose (TCID) concentrations to copy numbers. The same ATCC cultures used 
to establish the LOD for the GenMark multiplex assays in the FDA trial were used to perform 
these conversion experiments. ATCC cultures were extracted and various dilutions 
encompassing or, in the case of influenza B, approaching the reported LOD were targeted via 
qPCR using plasmids described in Appendix 1.A. The figures in this appendix help show how 
the concentrations were tracked throughout the process. Averages and standard deviations were 
calculated from three replicates at each TCID50/mL target dilution. These were used to produce a 
low, average, and high trend line from which to estimate copy numbers for reported TCID 
LODs. Averages and standard deviations were calculated to produce a final copy number value 
(per 5μL) at the reported GenMark LOD. Once converted, the copy number value was directly 
compared to the limits of detection (LOD) established for the singleplex assays in clinical 
background (Appendix 1.B). Copy number differences between the singleplex and multiplex 
(GenMark) assays are summarized in the table at the bottom of each figure.
53
Figure 1.C-1: Adenovirus (group C, VR-1) TCID concentration conversion to copy numbers,
GenMark RVP LOD to convert to copy numbers = 8.89 x 101 TCID50/mL.
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Figure 1.C-2: Adenovirus (group E, VR-1572) TCID concentration conversion to copy numbers,
GenMark RVP LOD to convert to copy numbers = 1.58 x 101 TCID50/mL.
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Figure 1.C-3: Influenza A (VR-547) TCID concentration conversion to copy numbers, CEID = 
chicken egg infectious dose, GenMark RVP LOD to convert to copy numbers = 1.58 x 103
CEID50/mL.
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Figure 1.C-4: Influenza A/H3 (VR-547) TCID concentration conversion to copy numbers, CEID 
= chicken egg infectious dose. The LOD for the multiplex GenMark influenza A/H3 assay exceeded 
the LOD of the qPCR assay and conversions are considered estimates based on continued trend lines 
beyond the LOD of the qPCR assay. GenMark RVP LOD to convert to copy numbers = 1.58 x 103 
CEID50/mL.
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Figure 1.C-5: Influenza A/H1N1 (VR-1736) TCID concentration conversion to copy numbers,
GenMark RVP LOD to convert to copy numbers = 1.05 x 10-1 TCID50/mL.
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Figure 1.C-6: Influenza B (VR-101) TCID concentration conversion to copy numbers, CEID = 
chicken egg infectious dose. The LOD for the multiplex GenMark influenza B assay exceeded the 
LOD of the qPCR assay and conversions are considered estimates based on continued trend lines 
beyond the LOD of the qPCR assay. GenMark RVP LOD to convert to copy numbers = 3.16 x 10-1 
CEID50/mL.
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Figure 1.C-7: Parainfluenza 1 (VR-94) TCID concentration conversion to copy numbers,
GenMark RVP LOD to convert to copy numbers = 2.81 x 10-2 TCID50/mL.
60
Figure 1.C-8: Parainfluenza 2 (VR-92) TCID concentration conversion to copy numbers,
GenMark RVP LOD to convert to copy numbers = 2.81 x 100 TCID50/mL.
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Figure 1.C-9: Parainfluenza 3 (VR-93) TCID concentration conversion to copy numbers,
GenMark RVP LOD to convert to copy numbers = 2.81 x 101 TCID50/mL.
62
Figure 1.C-10: RSVA (VR-1540) TCID concentration conversion to copy numbers, GenMark
RVP LOD to convert to copy numbers = 2.81 x 100 TCID50/mL.
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Figure 1.C-11: RSVB (VR-955) TCID concentration conversion to copy numbers, GenMark
RVP LOD to convert to copy numbers = 1.58 x 100 TCID50/mL.
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Figure 1.C-12: Rhinovirus (VR-1540) TCID concentration conversion to copy numbers. The 
LOD for the multiplex GenMark rhinovirus assay exceeded the LOD of the qPCR assay and 
conversions are considered estimates based on continued trend lines beyond the LOD of the 
qPCR assay. GenMark RVP LOD to convert to copy numbers = 1.58 x 10-3 TCID50/mL.
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Chapter 2 BioRad BioPlex® HIV Ag-Ab assay: Incidence of false positivity in a low-prevalence 
population and its effects on the current HIV testing algorithm2
2 Parker J, Carrasco A, Chen J. BioRad BioPlex® HIV Ag-Ab assay: Incidence of false positivity in a low- 
prevalence population and its effects on the current HIV testing algorithm. Journal of Clinical Virology, 
2019. 116: p. 1-3.
2.1 Abstract
The BioPlex® HIV Ag-Ab assay, unlike other HIV 1/2 antigen/antibody immunoassays, 
is capable of differentiating positive HIV-1 antibodies (Groups M and O) from HIV-2 antibodies 
and/or HIV-1 p24 antigen in a single test. The Alaska State Virology Laboratory (ASVL) 
adopted the BioPlex® HIV Ag-Ab assay early 2017 and can report on its performance in terms 
of false positivity in a low-prevalence population and its effects on the current HIV testing 
algorithm recommended by the Centers for Disease Control and Prevention (CDC). Specimens 
received between March 2017 and August 2018 were screened using the BioPlex® HIV Ag-Ab 
assay. Specimens screening positive for HIV antibodies or antigen were further confirmed using 
the Geenius™ HIV 1/2 Supplemental Assay and/or HIV RNA testing. Of the 12,338 sera 
screened for HIV, 35 specimens were positive on the BioPlex® HIV Ag-Ab assay. Only 22 of 
the specimens were able to be confirmed by the Geenius™ HIV 1/2 Supplemental Assay and 
were considered to be truly positive (PPV, 62.9%). RNA was not detected in these cases 
suggesting initial false positivity on the BioPlex® HIV Ag-Ab assay. True positive results had 
index values (IDX) of >180 whereas false positive IDX's were between 1 and 4, with the 
exception of one specimen. We suggest that specimens demonstrating positivity with low IDX 
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values <4 on the BioPlex® HIV Ag-Ab assay proceed directly to RNA testing, essentially 
bypassing supplemental antibody confirmation tests, to reduce turnaround time and cost of HIV 
confirmation.
2.2 Introduction
Broadening the detection window while improving HIV assay sensitivity has made a 
positive impact on HIV patient management and treatment. However, improved sensitivity in 
combination with other biological factors and technical issues can lead to false positive HIV 
results [1-4]. The HIV 1/2 antigen/antibody immunoassays have been shown to produce false 
positive results, especially in populations with low HIV prevalence [5, 6]. False positives are 
identified as specimens with low reactivity by initial HIV1/2 antigen/antibody immunoassays, 
which are unable to be confirmed by subsequent testing using varied methodologies, such as the 
Bio-Rad Geenius™ HIV-1/2 Supplemental Assay and PCR [4, 7-10].
BioRad's BioPlex® HIV Ag-Ab combination assay is a multiplex flow immunoassay 
that can simultaneously detect and differentiate HIV-1 p24 antigen, HIV-1 (groups M and O) 
antibodies, and HIV-2 antibodies in human serum or plasma. It reportedly produces the best 
analytical sensitivity of HIV-1 p24 antigen on the market (limit of detection, 0.33 IU/mL and 5.2 
pg/mL) as well as high specificity in low risk population (99.86%) [11]. The assay has been 
shown to be effective in identifying early cases of HIV when compared to other automated 
platforms [12]. The BioPlex® HIV Ag-Ab assay is not widely used in public health settings at 
this time but offers a clear advantage in terms of reducing labor while improving diagnostics by 
separating antigen-antibody combination results into individual measurements in a fully 
automated manner. In this study, we look at the false positivity rate and positive predictive value 
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when using the BioPlex® HIV Ag-Ab combination assay in a low HIV prevalence population 
and provide insight on its effects on the recommended HIV testing algorithm.
2.3 Methods and Materials
A total of 12,338 sera were collected from patients ranging from age 2 to 92 (median age 
= 29, interquartile range = 23 to 38 years old) between March 2017 and August 2018 from 
various regions across Alaska and sent to the ASVL for surveillance purposes.
Specimens were screened using the BioPlex® HIV Ag-Ab assay on the BioPlex® 2200 
instrument. Results are expressed as an index value (IDX) describing the measured RFI (relative 
fluorescent intensity unit) as a ratio to the cut-off value for each particular bead type. Four 
separate results were generated for each multiplexed test, where IDX values of > 1 were 
considered reactive: 1) HIV Ag/Ab combo, undifferentiated, 2) HIV-1 antibody, 3) HIV-1 
antigen, and 4) HIV-2 antibody. Specimens that exhibited any level of reactivity were confirmed 
using the Geenius™ Supplemental HIV 1/2 Antibody assay. RNA testing had to be referred to a 
different laboratory and therefore this process was reserved for specimens testing positive for 
HIV p24 antigen without evidence of antibody presence as well as settling any discrepancies 
between the BioPlex® HIV Ag-Ab assay and the Geenius™ Supplemental HIV 1/2 Antibody 
assay.
2.4 Results
The majority of specimens tested belonged to patients aged 19 to 45 years old (75.6%). 
Representative of typical low HIV prevalence in Alaska, only 35 specimens demonstrated 
presence of HIV antibodies and/or p24 antigen (0.28%) during routine HIV screening. Of these 
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35 positive specimens, 22 (0.18% of total) were confirmed using the Geenius™ assay. The 
remaining 13 specimens that could not be confirmed were referred to Wadsworth Center, 
Albany, NY) for nucleic acid testing (NAT) (Supplemental table), with the exception of 3 
specimens which did not have enough serum volume left at this stage of the algorithm. Patients 
were contacted in these cases and specimens were redrawn to provide additional serum to 
complete the algorithm. One specimen demonstrated positivity for HIV-1 and HIV-2 antibodies, 
but could only be tested for HIV-1 RNA due to lack of specimen volume. An additional 
specimen was redrawn in this case and retested to provide serum for HIV-2 RNA NAT. The 
positive predictive value in the Alaska population tested was 62.9% (TP/(TP+FP), 22/(22+13)). 
Of the 22 true positives, 21 specimens (95.5%) were positive for HIV-1 antibody only. The other 
true positive specimen demonstrated positivity for both HIV-1 antibody and HIV-1 p24 antigen. 
Of the 13 false positive reactions, 5 (38.5%) were positive for HIV-1 antibody only, 5 (38.5%) 
were positive for HIV-1 p24 antigen only, and 3 (23.1%) were positive for all targets (HIV-1 and 
HIV-2 antibodies as well as HIV-1 p24 antigen).
Table 2.1 describes average IDX values produced by the BioPlex® HIV Ag-Ab assay for 
each targeted analyte by result type. Most false positive reactions demonstrated an IDX 
measurement <4 with the exception of one specimen which measured between 11-12 IDX for 
HIV-1 antibody. On average, true positive reactions measured 10-fold higher (>180 IDX) when 
compared to false positive IDX values. Additional details describing test outcomes for specimens 
testing falsely positive can be found in Table 2.2.
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2.5 Discussion
Low prevalence of HIV infection in a population can lend itself to increased false 
positivity on diagnostic tests. For instance, BioRad Laboratories tested 6,395 patients in a low- 
risk population and found that 28 were repeatedly reactive for HIV using the BioPlex® HIV 
assay (specificity of 99% and sensitivity of 100%). Only 19 of these positives could be 
confirmed with the Geenius™ Supplemental HIV 1/2 assay and/or NAT testing (19/(19+9) = 
67.9% PPV) [11], which is similar to this study (62.9%). This demonstrates that the BioPlex 
assay performed as intended in a low-prevalence setting. Although this isn't optimal, other HIV 
1/2 antigen/antibody immunoassays have reported even lower PPVs, such as the Abbott 
Architect HIV antigen/antibody combination assay which demonstrated a PPV of 31.2% with 
significant PPV differences when testing sera from males (49.9%) vs. females (2.5%) [6].
Algorithm adjustments have shown to decrease the likelihood of false positives in various 
populations. In one study, PPV was improved by using two separate HIV 1/2 antigen/antibody 
immunoassays during the screening process, in this case the Abbott Architect used in 
conjunction with the Vidas HIV Duo Ultra (97% PPV) [13]. A PPV of 83% was demonstrated 
on the Abbot Architect by considering significantly lower signal-to-cutoff ratios in a study 
focused pregnant women, a group that sometimes experiences higher rates of false positive HIV 
test results [14].
In our study, all false positive results demonstrated low IDX values, with the exception of 
one specimen. Based on our results, we suggest that caution be applied to any low positive 
BioPlex® HIV Ag-Ab assay IDX value (< 4) when reporting preliminary HIV results. Also, 
supplemental antibody testing provided by the Geenius™ assay did not enhance HIV test 
interpretation. Sensitive RNA testing, however, helped rule out the presence of detectable virus, 
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which allowed for the final conclusions of each false positive test result. Adjustments to the 
testing algorithm to bypass the supplemental antibody assay if the BioPlex® HIV Ag-Ab assay 
generates low positive IDX values may be helpful to reduce cost, labor, and turnaround time by 
following through directly to NAT testing (Figure 2.1).
The BioPlex® HIV Ag-Ab assay will likely become more common among laboratories 
conducting HIV surveillance based on its technical ability to further characterize HIV positive 
specimens as well as reduce labor. In order to address the issue of false positivity in low- 
prevalence populations, laboratories choosing to adopt the BioPlex® HIV Ag-Ab assay may 
want to consider bypassing the supplemental confirmation assay for specimens exhibiting low 
BioPlex® IDX values and proceed to RNA testing. Similar strategies have been considered for 
BioPlex® HIV-1 p24 Ag positive-only results [15]. This will ensure that weaker reactions 
obtained during HIV Ag-Ab combination screening are followed up to test for the presence of 
viral RNA indicating true HIV infection.
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Table 2.1: Comparison of BioPlex® HIV ag-ab assay IDX values by result type
Result Type # specimens Specimen Transit
Time (days)
HIV AgAb HIV-1 Ab HIV-1 Ag HIV-2 Ab
True Positive 22 4.55 ± 1.57 187.49 ± 35.45 187.49 ± 35.45 0.52 ± 0.87 0.17 ± 0.08
False Positive 13 3.85 ± 1.77 2.58 ± 2.90 2.06 ± 3.03 1.09 ± 1.11 0.50 ± 0.60
Negative 12,303 4.52 ± 2.40 <1.00 <1.00 <1.00 <1.00
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BioPlex® HIV Ag-Ab assay Results (IDX values)
Geenius™ NAT
HIV Ag-Ab HIV-1 Ab HIV-1 Ag HIV-2 Ab
AK#1 19 Female Unknown 1.21 (± 0.07) 0.49 (± 0.04) 1.21 (± 0.07) 0.54 (± 0.04) HIV Neg HIV1 ND
AK#2 20 Female Unknown 1.43 (± 0.11) 0.62 (± 0.08) 1.43 (± 0.11) 0.70 (± 0.12) HIV Neg HIV1 ND
AK#3 22 Male Inmate 3.71 (± 0.38) 2.24 (± 0.16) 3.71 (± 0.38) 2.19 (± 0.09) HIV Neg HIV1 ND
redraw 2.14 (± 0.08) 1.51 (± 0.10) 1.91 (± 0.36) 1.57 (± 0.55) NP HIV2 ND
AK#4 26 Female Pregnant 1.07 (± 0.05) 1.07 (± 0.05) 0.17 (± 0.01) 0.08 (± 0.03) HIV Neg HIV1 ND
AK#5 35 Female Unknown 2.77 (± 0.09) 1.01 (± 0.02) 2.77 (± 0.09) 1.07 (± 0.02) HIV Neg HIV1 & HIV2 ND
AK#6 38 Male Unknown 11.77 (± 0.30) 11.77 (± 0.30) 0.08 (± 0.03) 0.06 (± 0.02) HIV Neg HIV1 ND
AK#7 39 Female Pregnant 1.05 (± 0.13) 0.49 (± 0.06) 1.05 (± 0.13) 0.52 (± 0.02) HIV Neg QNS
redraw 0.95 0.48 0.95 0.51 NP NP
AK#8 45 Male Inmate 1.01 (± 0.07) 1.01 (± 0.07) 0.24 (± 0.03) 0.18 (± 0.05) HIV Neg HIV1 ND
AK#9 67 Male Unknown 3.19 (± 0.14) 3.19 (± 0.14) 0.11 (± 0.03) 0.08 (± 0.02) HIV Neg HIV1 ND
AK#10 40 Female Pregnant 1.65 (± 0.12) 1.65 (± 0.12) 0.26 (± 0.06) 0.13 (± 0.03) HIV Neg QNS
redraw 1.97 (± 0.08) 1.97 (± 0.08) 0.44 (± 0.10) 0.26 (± 0.03) HIV Neg HIV1 ND
AK#11 52 Male Inmate 1.46 (± 0.32) 0.20 (± 0.03) 1.55 (± 0.20) 0.10 (± 0.02) NP HIV1 ND
AK#12 15 Male Inmate 2.04 (± 0.13) 2.04 (± 0.13) 0.42 (± 0.09) 0.25 (± 0.03) HIV Neg HIV1 ND
AK#13 36 Male Unknown 1.13 (± 0.23) 0.95 (± 0.20) 1.13 (± 0.23) 0.64 (± 0.08) HIV Neg QNS
redraw 0.77 0.63 0.77 0.45 NP NP
*Index Values > 1.0 are considered reactive. Reactive specimens tested in triplicate. Confirmation was performed on specimens exhibiting 
reactivity on any bead result. ND - RNA Not Detected, QNS - quantity of serum not sufficient for further evaluation, NP - not performed. 
The BioPlex® HIV Ag-Ab assay is a screening method while the Geenius and NAT (nucleic acid amplification test) are considered 
confirmatory methods. Specimens AK#3, #7, #10, and #13 were redrawn and tested again due to insufficient quantities from the initial blood 
draw for confirmation testing.
Figure 2.1 Current recommended HIV testing algorithm showing suggested 
modifications in red [2].
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Chapter 3 Application of Next Generation Sequencing for the Detection of Human Viral Pathogens 
in Clinical Specimens3
3 This chapter blends and expands upon the following two manuscripts which can be found in their exact 
published forms in Appendices B and C, respectively:
Parker J, Chen J. Application of next generation sequencing for the detection of human viral pathogens in 
clinical specimens. Journal of Clinical Virology. 2016; 86:20-26
Parker J, Chen, J. Next generation sequencing in clinical virology diagnostics. Clinical Lab International, 
Feb/Mar 2017:6-9.
3.1 Abstract
Next generation sequencing (NGS) is a new technology that can be used for broad 
detection of pathogens and is rapidly becoming an essential platform in clinical laboratories. It is 
not known how NGS will displace or enhance gold standard methodologies in infectious disease 
diagnosis. To investigate the feasibility and application of NGS technology in public health 
laboratories and compare NGS technology with conventional methods, Illumina's MiSeq system 
was used to detect viral pathogens alongside other conventional virology methods using typical 
clinical specimen matrices. Sixteen clinical specimens and two CDC proficiency panels 
containing seventeen specimens were analyzed. Known pathogenic viral nucleic acid was 
positively identified in all clinical specimens, correlating and building upon results obtained by 
more conventional laboratory methods. Sequencing depths ranged from 0.008X to 319X and 
genome coverage ranged from 0. 6% to 99.9%. To qualify the described methods used to analyze 
data derived from clinical specimens, the results of a clinical proficiency panel are also 
presented. These results reveal true scarcity of known pathogenic viral nucleic acids in clinical 
specimens. NGS outperforms conventional detection methods in this study by turnaround time as 
well as the improved depth of knowledge in regards to serotyping and drug resistance.
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3.2 Introduction
Methodologies to detect pathogenic viruses in clinical specimens have transitioned from 
classic cell culture and antibody-antigen techniques to more sensitive molecular methods such as 
polymerase chain reaction (PCR). The targeted nature of these methodologies hinders their 
ability to accommodate the true diversity of human pathogens in a clinical specimen, especially 
viruses [1]. Next generation sequencing (NGS) technologies are quickly demonstrating their 
ability to provide broad detection of infectious agents in a target-independent manner [2-7]. 
NGS has many advantages beyond the improved detection of all suspected, unsuspected, or even 
novel pathogens in a clinical specimen [8]. Familiarization with pathogen genomic sequences 
within clinical specimens enhances our understanding of infectious disease through further 
discovery of pathogen variability and genotyping [9-13] , drug resistance or response to therapy 
[14-16], vaccine development and efficacy monitoring [17], and further characterization of the 
metagenome [18, 19]. The use of NGS for routine use in clinical diagnostics is emerging with its 
own set of limitations and challenges [13, 20]. Focusing on viruses of public health importance, 
we compared the performance of NGS alongside other more common viral detection 
methodologies.
3.3 Methods and Materials
3.3.1 Specimens
Sixteen previously tested clinical specimens, swab and serum specimens, were 
provided by the Alaska State Virology Laboratory in Fairbanks, Alaska. Two proficiency 
panels with a combined seventeen specimens for detecting antiviral resistance markers in 
the neuraminidase gene of influenza A virus were also tested as a quality indicator of this 
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process. Proficiency specimens consisted of cultured Madin-Darby Canine Kidney 
Epithelial (MDCK) cells infected with influenza A virus.
3.3.2 Construction of sequencing library
Nucleic acid was isolated from 500μL of the original clinical specimen using 
phenol/chloroform followed by ethanol precipitation. DNA or RNA molecules were 
selected by using DNase I (serum and proficiency specimens) or RNAse (swab 
specimens, with the exception of the influenza specimens). Quantity was evaluated using 
the Qubit instrument (Thermo Fisher Scientific) and the Agilent Bioanalyzer. The 
Nextera DNA Specimen Preparation protocol (Illumina, [21]) and the NEBNext Ultra 
RNA Library Prep Kit protocol (New England Biolabs, [22]) were followed to prepare 
sequencing libraries.
3.3.3 Next generation sequencing and data analysis
Libraries underwent paired-end sequencing on the Illumina MiSeq using a v.2 
500-cycle kit. Read files were imported into Pathseq™Virome for reference genome 
identification. Alignments to the identified viral genome sequence(s) were performed by 
Sequencher (v5.1) in addition to an external tool, Genomic Short-read Nucleotide 
Alignment Program (GSNAP) [23]. Read depth and genome coverage was established 
using Tablet (v.1.13.12.17, [24]).
3.3.4 Conventional Viral Detection Methods
Tests performed in addition to NGS on the swab specimens included cell culture, 
fluorescent microscopy, and serum neutralization for serotyping isolates that were 
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successfully grown in cell culture. Tests performed in addition to NGS on the serum 
specimens included an enzyme-linked immunosorbent assay (ELISA) to determine the 
presence of ICV antibodies (Roche). Proficiency specimens were also screened by real­
time quantitative PCR (qPCR) prior to NGS. Brief descriptions of these more 
conventional methodologies are described next.
3.3.4.1 Viral Culture
A portion of each specimen (0.3mL) was inoculated into fresh cell 
monolayers of MRC-5, IEp-2, and RMK cells (Diagnostic Iybrids). Infected 
cultures were then placed in 35°C (±2°C) incubators. Cultures were observed for 
cytopathic effect (CPE) by light microscopy periodically over 1-14 days. CPE 
was rated on a scale of 1+ to 4+, where 1+ =25% cells with CPE, 2+ =50% cells 
with CPE, 3+ =75% cells with CPE, and 4+ =100% cells with CPE.
3.3.4.2 Fluorescent Microscopy
When CPE was observed (>2+), infected cell monolayers were scraped, 
dispensed in duplicate onto 8-well slides, dried, and fixed with acetone. Once 
fixed, slides were dried and subjected to various commercial fluorescent stains 
containing specific monoclonal or polyclonal antibodies targeting a particular 
virus. Procedures were carried out according to manufacturer instructions [25, 
26] and fluorescence was assessed using a fluorescent microscope and positive 
(in-house lots) and negative control slides.
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3.3.4.3 Serum Neutralization (SN) assay
Once CPE was observed and the virus was identified as an adenovirus, the 
culture was diluted 1:10 and subjected to incubation in the presence of different 
monoclonal antibodies representing various serotypes of adenovirus. Initially, 
each chosen monospecific antisera was heat inactivated at 56°C for 30 minutes. 
A 1:10 dilution of the isolate was added 1:1 v/v to the heat-inactivated antisera. 
The antigen-antibody complexes were allowed to react for 1 hour at room 
temperature. Following incubation, HEp-2 cell monolayers were infected with 
each antigen-antibody reaction and allowed to incubate for 1.5 hours at 37°C. 
The growth media was then replaced with cell culture maintenance media. Viable 
virus was allowed to grow at 33°C on a test tube roller. Cultures were checked 
for CPE for up to 7 days using light microscopy. Cultures producing no CPE, 
suggesting the virus was successfully neutralized, were considered to contain that 
particular serotype of adenovirus.
3.3.4.4 Enzyme-Linked Immunosorbant Assay (ELISA)
Specimens were processed per manufacturer instructions using the 
EVOLIS analyzer (BioRad, Inc.) in combination with the HCV v.3 antibody 
detection kit (Roche) [27].
3.3.4.5 Real-time quantitative PCR (qPCR)
qPCR was performed as previously described to screen specimens for 
influenza prior to preparing the specimens for NGS [28, 29].
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3.3.5 Comparative Sequencing Method - Pyrosequencing
Consensus results from pyrosequencing (Roche 454) were obtained from 
laboratories participating in the proficiency panel for the detection of antiviral-resistant 
influenza A/H1N1pdm09 and influenza A/H3N2 viruses. These results were compared to 
those obtained by the next generation sequencing process described in section 3.3.3.
For pyrosequencing, specimens were prepared by first performing PCR to create 
amplicons of a portion of the neuraminidase gene. Particular amino acids motifs, as 
translated from bases in this amplicon, indicate resistance or susceptibility to current 
influenza neuraminidase-inhibitors (oseltamivir, zanamivir, and peramivir). Wild-type 
influenza A/H1N1pdm09 has two known amino acid positions that lessen their 
susceptibility to current influenza antivirals: H275Y (histidine to tyrosine) and I223K 
(isoleucine to lysine). Wild-type influenza A/H3N2 viruses have three known amino acid 
positions that lessen their susceptibility to current influenza antivirals: E119V (glutamic 
acid to valine), R292K (arginine to lysine) or N294S (asparagine to serine). Wild-type 
influenza B viruses have seven known amino acid positions that lessen their susceptibility 
to current influenza antivirals: E105K (glutamic acid to lysine), E117A/G (glutamic acid 
to alanine or glycine), Q138K/R (glutamine to lysine or arginine), P139S (proline to 
serine), G140R (glycine to arginine), D197N/E (aspartic acid to asparagine or glutamic 
acid), I221T/R/V/L (isoleucine to threonine, arginine, valine, or leucine), H273Y/R 
(histidine to tyrosine or arginine), and N294S (asparagine to serine).
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3.4 Results
3.4.1 NGS for detecting clinical adenovirus infections
Two infections were able to be diagnosed and further characterized using NGS 
(Figure 3.1). The first, a nasopharyngeal swab from a two-year-old male, was cultured 
and identified as serotype 2 adenovirus. This process took a total of 14 days to complete. 
PathSeq Virome analysis identified Human Adenovirus C strain 
human/ARG/A51932/2002/2 (JX173079) among the NGS read files. Read coverage was 
low for this specimen (0.4X) covering only 26.7% of the adenovirus genome. This 
included 30.2% of the hexon gene (3 fragments, average length 292bp), which is used to 
differentiate adenovirus [30]. The 3 gene fragments sequenced from this region 
accurately aligned with reference sequence NCBI AC_000007.1 with >99% similarity to 
adenovirus. Two of the regions further identified the virus as a serotype 2 adenovirus.
The second specimen, a nasal swab from a 29-year-old female, was cultured and 
demonstrated adenovirus-like CPE at day eight and was successfully typed as serotype 3 
adenovirus 18 days later. PathSeq Virome analysis identified Human Adenovirus B 
strain (human/USA/ UFL_Adv3a51/ 2007/3 (KF268123)). Alignment to this reference 
strain using GSNAP showed 585 reads with 3.7X depth and 87.9% genome coverage.
3.4.2 NGS for detecting clinical herpesvirus infection
The herpesvirus results of three specimens were further characterized using NGS 
(Figure 3.2). Clinical diagnostic tests were performed on two swabs taken from genital 
lesions, one from a 36-year-old female and another from a 41-year-old female. 
Herpesvirus was suspected in both cases and viral culture was chosen to diagnose or rule- 
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out the infection. Both specimens demonstrated CPE overnight and the one was clearly 
diagnosed as a herpesvirus 1 infection by immunofluorescent staining. PathSeq Virome 
analysis of the NGS data identified human herpesvirus 1 strain H129 (GU734772). 
When aligned to this reference sequence using GSNAP, a total of 3,664 read files aligned 
with 5.3X depth and 79.4% genome coverage.
The other specimen was also cultured, but subsequent staining was indeterminate 
and had to be repeated with various wash buffers to optimize the assay and get a positive 
identification of a human herpesvirus 2. An aliquot of the culture isolate was extracted 
and underwent NGS to confirm. PathSeq Virome analysis identified read files belonging 
to Human herpesvirus 2 strain SD90e (KF781518). When NGS files were aligned to this 
reference sequence using GSNAP, 171,146 reads were present representing 99.3% of the 
genome at 199X depth. This example demonstrates the ability of non-targeted NGS to 
confirm indeterminate findings from traditional, targeted methodologies. As expected, the 
overall proportion of viral reads is much higher when sequencing clinical isolates (>15%) 
as compared to raw clinical materials (<1%).
Human herpesvirus 5 (cytomegalovirus) was found to be present in a third 
specimen, a nasopharyngeal swab taken from a 3-year-old female. As is typical for slow 
growing cytomegalovirus, the culture incubated for 14 days before showing distinctive 
CPE for staining. PathSeq Virome analysis indeterminately identified the 
cytomegalovirus as human herpesvirus 5 strain HAN2 (JX512200). GSNAP alignment 
to this reference only identified 8 reads (0.008X, 0.6% genome coverage). However, 
PathSeq Virome analysis more definitively identified torque teno virus isolate US32 
(AF122921). A GSNAP alignment to this reference identified 585 read files (3.7X, 88% 
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genome coverage). Surveillance for torque teno viruses is not common since they are 
thought to be ubiquitous in humans and lack concrete disease association, unlike 
cytomegalovirus [31, 32]. Cytomegaloviruses are also ubiquitous in the human 
population; however, they have direct associations with disease when latent viruses are 
reactivated. The risk of reactivation is higher for immune suppressed patients which, if 
not iatrogenic, may be due to underlying medical conditions [32]. The results of this 
specimen demonstrate the benefit of combining methodologies in some circumstances to 
get a clearer interpretation of the patient's status. Low sequence coverage of the 
cytomegalovirus isolate is thought to be due to such low representation overall compared 
to the background metagenome (0.0005%).
3.4.3 Further characterization of viral hepatitis C and G viruses
Methodologies to compare NGS's ability to detect hepatitis C was not evaluated, 
but rather sequence analysis was performed to discover how NGS could be used to 
further characterize the virus. Specimens were all positive for genotype 1a HCV and 
specific isolates were identified by PathSeq™Virome (Figure 3.3).
New direct acting antiviral therapies have been designed to target and impair the 
functions of non-structural proteins, NS3/4A, NS5A, and NS5B. In response, 
breakthrough mutations in these particular viral genes have demonstrated antiviral 
resistance to certain HCV antiviral therapies [33-37]. Figure 3.3 summarizes resistance 
data obtained by NGS for each protein targeted as well as the antiviral therapies that are 
associated. Isolate identified as V60-like was found to have one mutation affecting 
susceptibility to NS5A-inhibitors (M38V) and 2 mutations affecting susceptibility to
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N3/NS4-inhibitors (T54S and Q80K). Three other isolates, identified as V179-, V173-, 
and V269-like, each showed 1 mutation leading to reduced susceptibility to N3/NS4- 
inhibitors (Q80K).
Figure 3.3 also shows that hepatitis G virus (IGV) isolates were simultaneously 
identified in three of the five specimens tested (60%). It is known that IGV infections 
are closely associated with ICV infections due to parallel routes of transmission [38, 39]. 
Although not commonly practiced, more thorough surveillance of IGV infections in 
humans may be necessary due to indications that it is a significant player in determining 
the course and prognosis of other diseases such as IIV, ICV, and even diseases of the 
brain [5, 39]. NGS is an appropriate method to detect and characterize both ICV and 
IGV viruses in parallel.
3.4.4 Antiviral resistance of influenza viruses in clinical specimens
Data is provided for six nasopharyngeal swab specimens containing influenza 
viruses tested by PCR methods and NGS (Figure 3.4). NGS results detected regions of 
the genome attributed to antiviral drug resistance, as previously described [40-42]. 
Genome-wide diagrams of alignments to reference genomes produced by Tablet illustrate 
the various coverages obtained for each clinical specimen (Figure 3.4). Large variations 
amongst the results are attributed to the quantity of virus in the original clinical specimen 
since enrichments techniques such as filtration or centrifugation were not used. 
Identification of polymorphisms, especially those occurring at specific positions of the 
neuraminidase gene, may indicate various levels of antiviral resistance to neuraminidase 
inhibitors and serves as an important piece of information in terms of influenza 
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surveillance. No variants were detected amongst the clinical specimens analyzed (all wild 
type). For influenza A/H3, one specimen was missing sequence information for one 
amino acid motif, 119. For influenza B, one specimen was missing the entire NA gene 
and could not be analyzed.
Results of a proficiency panel intended for laboratories using pyrosequencing 
methods are compared to those obtained by NGS (Table 3.1). Results of NGS had 100% 
concordance with pyrosequencing results for distinguishing wild-type and variant viruses 
by identifying mutations in the specific amino acid motifs in the neuraminidase gene as 
an indicator of antiviral resistance. NGS revealed low coverage sequence reads in 
negative specimens (10 reads each for PT-A-1 and PT-A-4) revealing the need to 
establish a standard in which to confidently distinguish non-specific and specific reads in 
NGS data.
3.4.5 Non-specific viral sequencing reads in NGS data
Low coverage viral sequencing is an issue when working with clinical specimens. 
Collections from patients represent a wide array of pathogen quantities. Although 
sequencing is becoming more competitive with other conventional methodologies in 
terms of cost, there is a need for increasing sequencing depth in order to detect 
pathogenic viruses in clinical specimens. Deeper sequencing also allows for a greater 
chance of detecting non-specific viral reads. For instance, other viruses were considered 
“poorly” detected by Pathseq™Virome in each clinical specimen; however, these results 
could not be substantiated by GSNAP alignments due to very few reads and coverages.
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Like other clinical assays, NGS needs a cutoff to determine the true presence of a 
pathogen versus carry-over or contamination between specimens or other non-specific 
reads. True negative proficiency specimens (PT-A-1 and PT-A-4) contained 10 reads 
aligning to the H1N1 NA reference gene (false positive) whereas the human herpesvirus 
5 that grew from a nasopharyngeal swab also only had 10 reads. Indeterminate results, 
such as these, may need to undergo repeat testing where more involved enrichment 
techniques can be employed to determine the true presence of a virus in low-titer clinical 
specimens.
3.5 Discussion
Applications of NGS in a clinical laboratory were considered to characterize pathogenic 
viruses of public health importance. NGS data was compared to data obtained by more 
conventional methods of virus detection. DNA viruses such as adenoviruses and herpesviruses 
and RNA viruses such as hepatitis C virus and influenza virus were further characterized in these 
experiments. In most cases, with the exception of one herpesvirus, information retrieved by NGS 
met or exceeded that of conventional methodologies. Beyond mere detection, NGS proved to be 
a laboratory tool capable of predicting the effects of drug treatment as well.
The importance of characterizing pathogenic viruses in clinical specimens should not be 
undermined by the fact that very few treatments are available for viral infections. However, for 
infections caused by viruses with available antiviral drug treatments, known resistance markers 
in the viral genome could be routinely monitored using NGS. This would allow for surveillance 
of drug effectiveness against circulating strains of viruses in particular populations.
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Adenoviruses are widely distributed amongst humans and generally cause only mild 
acute respiratory illness. However, some serotypes are more virulent and can be associated with 
outbreaks, severe pneumonia, and possibly cancer such as serotypes 14, 55, and 12 [30, 43]. As 
recent as November 2018, serotype 7 was implicated in an outbreak of respiratory illness in New 
Jersey where 11 children died [44]. NGS, which was complete in approximately 4 days 
compared to the 14 - 18 days required for culture and serotyping, demonstrated to be a powerful 
tool for characterizing adenovirus infection when compared to traditional methodologies. 
Routinely sequencing adenoviruses could prove useful in monitoring how closely circulating 
strains match vaccine candidates for serotypes 4 and 7, two viruses responsible for severe 
respiratory illness among military recruits [45].
Other DNA viruses, such as herpes simplex viruses, grow very quickly in culture, but 
particular strains can be difficult to positively identify using immunofluorescence assays alone 
due to non-specific staining. NGS confirmed indeterminate staining results and further 
characterized the virus isolate as a specific human herpesvirus 2 strain. Sequencing data with 
this level of resolution of the herpesvirus genome could be used to identify transmission routes to 
relate infections between people. This type of information could be used to determine the source 
of the infection as well as bring additional benefit to epidemiologic and forensic data. Like 
adenovirus infections, herpes simplex viruses have available antiviral treatment options. 
Sequencing data could be used to evaluate the effectiveness of antivirals on specific strains by 
routinely monitoring markers of antiviral resistance.
One herpesvirus infection caused by cytomegalovirus (HHV5) was unable to be 
adequately sequenced and characterized due to suspected low initial viral titer in the original 
clinical specimen (i.e. minimal starting template). Culturing the specimen, in this case, could 
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amplify the virus into higher titers that could provide more starting template to be sequenced, 
much like that which was demonstrated in the confirmation of the human herpesvirus 2 
specimen. Some hesitancy to culture the virus is understandable, especially when working with 
viruses with high mutation rates, like RNA viruses. DNA viruses, like herpesviruses, have lower 
rates of mutation in comparison to their single-stranded counterparts. Therefore, culturing has 
less of an effect on the final sequences of what is considered to represent the original herpesvirus 
genome.
Hepatitis C virus (HCV) is a growing concern for public health and tends to be difficult 
to design targeted methodologies around due to the high variability of viral genomes known, 
even within the same patient. NGS is a powerful tool for characterizing HCV infections and, 
from this experience, more informational than targeted genotyping assays. Since these methods 
produce sequences of the entire HCV genome (coverage ranged from 92.4% - 95.6%), data could 
be generated describing the mutations at key locations across the genomes that are known to 
cause drug resistance.
Antiviral resistance is also critical when characterizing current circulating influenza virus 
strains and NGS was able to identify viruses that would be considered susceptible to 
neuraminidase inhibitors. In two cases, the viral load of the specimen was too low to achieve 
good genome coverage across the neuraminidase gene, but this issue could be resolved by 
screening specimens for high titer (i.e. qPCR) or utilizing enrichment techniques such as 
ultracentrifugation, filtration of other background nucleic acid, or viral isolation via culture.
Through increased use of NGS technologies, reference databases of whole genome 
sequences of viral pathogens can grow and enhance our ability to more definitively identify 
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sequencing reads. Although these experiments describe concurrency between conventional 
methods and NGS, there was also evidence of unexpected viruses, such as of the presence of co­
infecting viruses like hepatitis G and torque teno virus. The standard 4-day turnaround time 
needed to complete NGS could be improved with extraction and library preparation automation, 
as well as advances in sequencing technology (each run ~40 hours). Based on these outcomes 
and the growing body of literature, NGS will change our approach as clinical laboratorians and 
improve our ability to detect and more fully characterize agents of infectious disease in clinical 
specimens in a non-targeted manner. These improvements to pathogen characterization can also 
be a powerful epidemiological tool in its ability to relate cases, as we will see in Chapter 4.
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Reads % NA DepthH% Y%
PT-A-1 ND indeterminate -- -- -- -- -- -- 10 35.9% 1.3
PT-A-2 H1N1pdm09 H275 100 0 100 100 0 100 5728 99.6% 850
PT-A-3 H1N1pdm09 H275Y <10 >90 100 8 92 100 275 98.6% 38.3
PT-A-4 ND indeterminate 10 48.0% 1.6
PT-A-5 H1N1pdm09 H275Y 60-65 35-40 100 68 42 100 3165 99.8% 436
PT-A-6 H1N1pdm09 H275 100 0 100 100 0 100 2589 98.9% 361
PT-A-7 H1N1pdm09 H275 100 0 100 100 0 100 1364 99.1% 204
PT-A-8 H1N1pdm09 H275Y 60-65 35-40 100 59 41 100 3624 99.7% 497
PT-A-9 H1N1pdm09 H275Y 100 0 100 100 0 100 8878 99.6% 1427
PT-A-10 H1N1pdm09 H275, I223K 100 0 0 100 0 0 4924 99.6% 764
PT-B-1 Not tested H275 100 0 100 100 0 100 12,788 99.8% 639
PT-B-2 Not tested H275Y 0 100 100 0 100 100 8,031 99.9% 402
PT-B-3 Not tested H275, I223K 100 0 0 100 0 0 10,139 99.9% 508
PT-B-4 Not tested H275Y 60-65 35-40 100 60 40 100 11,496 99.9% 575
performing pyrosequencing for currently circulating influenza A viruses. Known amino acid positions are unique to each type of 
neuraminidase gene (N1 or N2) separating out the viruses and varying the positions monitored for antiviral resistance.
H3N2 E119 R292 N294 E119 R292 N294
PT-B-5 Not tested 100 100 100 100 100 100 8,059 99.9% 418
PT-B-6 Not tested E119V 0 (V100%) 100 100 0 (V100%) 100 100 12,878 99.9% 670
PT-B-7 Not tested R292K 100 0 (K100%) 100 100 0 (K100%) 100 30,550 99.9% 1,585
Two separate panels of proficiency specimens (A & B) were tested using NGS and compared to results obtained by laboratories
Figure 3.1: Comparison of NGS and conventional virology assays for detecting adenovirus 
infection. Iep#2 cells, Diagnostic Iybrids; CPE, cytopathic effect, CPE scale, 1+ (25% cells 
with CPE), 2+ (50% cells with CPE), 3+ (75% cells with CPE) and 4+ (100% cells with CPE); 
DFA, Direct Fluorescence Assay, Diagnostic Iybrids; TAT, turnaround time indicating days 
needed to complete the analysis process. Pie charts show the total number of reads (and data 
storage needed in compressed files, .gz) in relation to the number of viral reads obtained for a 
particular virus. Exploding bar graph shows the percentage of the full genome that was identified 
by the reported number of reads.
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Figure 3.2: Comparison of NGS and conventional virology assays for detecting herpesvirus 
infection. Three clinical specimens from patients infected with different types of herpesvirus 
were tested by NGS and the results were compared with those obtained by different 




Figure 3.3: Detection and characterization of hepatitis C and G viruses in 5 different sera using NGS.
Three groups of antiviral drugs are shown targeting proteins NS5A, NS5B, and N3/N4A. Isolates (i.e. V60, V179) should be 
thought of as V60-like or V179-like, as identified by sequence analysis. Blackened columns of amino acids indicate that one or 
more isolates were found to have mutations at those positions associated with antiviral resistance.
Figure 3.4: Antiviral resistance characterization of influenza viruses using NGS. Genome-wide 
views as produced by Tablet. Table is split into 3 influenza virus types, A/H3N2 viruses, 
A/H1N1 viruses, and B viruses. Whole genome metrics are compared to those obtained for the 
NA gene only. Segment 6, the NA gene, is boxed out for each specimen and exploded into a 
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Chapter 4 Investigation of a Canine Parvovirus Outbreak using Next Generation Sequencing4
4 Parker, J., M. Murphy, K. Hueffer and J. Chen. Investigation of a Canine Parvovirus Outbreak using Next 
Generation Sequencing. Scientific Reports, 2017. 7(1): 9633-9633.
4.1 Abstract
Canine parvovirus (CPV) outbreaks can have a devastating effect in communities with 
dense dog populations. The interior region of Alaska experienced a CPV outbreak in the winter 
of 2016 leading to further investigation of the virus due to reports of increased morbidity and 
mortality occurring at dog mushing kennels in the area. Twelve rectal-swab specimens from dogs 
displaying clinical signs consistent with parvoviral-associated disease were processed using next­
generation sequencing (NGS) methodologies by targeting RNA transcripts, and therefore 
detecting only replicating virus. All twelve specimens demonstrated the presence of the CPV 
transcriptome, with read depths ranging from 2.2X - 12,381X, genome coverage ranging from 
44.8% - 96.5%, and representation of CPV sequencing reads to those of the metagenome 
background ranging from 0.0015% - 6.7%. Using the data generated by NGS, the presence of 
newly evolved, yet known, strains of both CPV-2a and CPV-2b were identified and grouped 
geographically. Deep-sequencing data provided additional diagnostic information in terms of 
investigating novel CPV in this outbreak. NGS data in addition to limited serological data 
provided strong diagnostic evidence that this outbreak most likely arose from unvaccinated or 




Canine parvovirus type 2 (CPV-2) is a non-enveloped, single-stranded DNA virus that 
causes fatal gastroenteritis in young dogs [1]. The CPV-2 genome is 5323 nucleotides long and 
possesses at least 2 major open reading frames (ORFs) [2]. CPV-2 infections are associated with 
significant morbidity and mortality which can reach 91% in untreated pups [3]. Three variants of 
CPV type 2 are known, CPV-2a, CPV-2b, and CPV-2c, and are highly contagious due to 
suspected low infective dose requirements combined with high titers of transmissible virus in 
stools of affected dogs [4, 5]. The virus is highly resistant to environmental conditions and can 
remain viable outside of its host for at least a year [6].
CPV-2 infections are one of the most common causes of disease outbreaks in dense 
canine environments such as kennels or shelters, and timely diagnosis is important in order to 
control the number of affected individuals [7]. CPV is commonly diagnosed in veterinary clinics 
using rapid fecal enzyme-linked immunosorbent assays (ELISA) that target viral antigen. These 
tests have high specificity but poor sensitivity when compared to PCR or immune-electron 
microscopy [8]. Although PCR assays are more sensitive, they can cause difficulty in terms of 
result interpretation since they can detect live attenuated vaccine strains or produce positive 
results from dogs showing no symptoms of gastroenteritis. This requires veterinarians to 
associate PCR results with other clinical signs of CPV infection, the animal's history, and other 
laboratory parameters such as leukopenia [8, 9]. The performance of any of these antigen­
targeting methods are highly variable due to the known phenomenon of intermittent shedding of 
CPV during the earlier and later stages of disease [10]. Despite these diagnostic challenges, it 
has been shown that current ELISA and PCR methods are capable of detecting all three variants 
of CPV in spite of antigenic differences [11].
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Between January and April 2016, the interior of Alaska experienced an increased number 
of CPV cases [12-14]. Outbreaks of canine infectious disease in Alaska can be socially and 
economically detrimental due to the dense dog population needed to support the state sport, dog 
mushing. The interior of Alaska, in particular, has a concentrated population of dogs due to the 
increased presence of professional and recreational mushers operating various sized kennels of 
10-100+ sled dogs each. Every winter Alaska hosts many visiting mushers, national and 
international, who come to the area to train and race their own dogs. Additionally, Alaska hosts 
several high-profile international dog mushing races, including the Iditarod and the Yukon 
Quest. These large races frequently include groups of dogs ranging from 350-1350 animals in 
number, who utilize the same trails, rests stops and parking areas, allowing for extensive 
comingling and a high potential for disease transmission. Sick dogs can spread the virus through 
defecation on common trails, where other teams run and transport the virus back to their own 
kennels. In 2016, the interior of Alaska experienced a mild winter with less than the usual 
amount of snowfall, leading to accumulation of uncovered fecal material on common mushing 
trails. In response to the CPV-associated outbreak of disease, mushers were provided 
notifications throughout the 2016 race season, and were asked to not bring potentially infected 
dogs to races in order to help slow the progression of the outbreak. Recommendations were also 
made to isolate sick animals in individual kennels. Due to the perceived increased virulence of 
the CPV strain or strains associated with the outbreak, additional testing to further characterize 
the virus was pursued.
Sequence analysis of the VP2 gene, the most abundant and immunogenic protein 
produced for construction of the viral particle capsid, is used to help subtype and further 
characterize wildtype CPV [15-18]. Surveillance of this particular protein is critical for assessing 
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the potential efficacy of the current vaccination strategy and can also be used to relate individual 
infections in outbreak situations [19-22]. Beyond VP2 investigation, deep-sequencing of the 
whole genome has been shown to be useful in order to better understand the true nature of CPV 
molecular diversity and discover new variants [23, 24]. In this experiment, next-generation 
sequencing (NGS) was used to detect and characterize actively replicating CPV in rectal swabs 
of canines associated with a suspected outbreak in the interior of Alaska between January - April 
2016 by targeting RNA transcripts.
4.3 Materials and Methods
4.3.1 Specimens
Twelve rectal swab specimens representing two communities, A (n=5) & B (n=7), 
were collected for the sole purpose of disease diagnosis. Communities involved are 258 
kilometers (approximately 160 miles) apart. The University of Alaska Fairbanks 
Institutional Animal Care and Use Committee (IACUC) has determined that this research 
project did not require IACUC review. Protocol review is not required for diagnostics 
performed during the course of a disease investigation. All methods were carried out in 
accordance with relevant guidelines and regulations.
4.3.2 Referral Testing (serology, PCR, & genotyping)
Specimens were sent to Cornell University, Ithaca, NY for evaluation of CPV IgG 
and IgM antibodies using hemagglutination inhibition (HAI), nucleic acid using PCR, 
and genotyping (Table 4.1). Total antibody was evaluated, as well as the IgM to IgG 
ratio upon application of 2-mercaptoethanol to dissociate IgM antibody molecules. 
Laboratory interpretation guidelines suggest that a 4-fold or greater decrease in titer after 
2-mercaptoethanol treatment is evidence of recent parvovirus exposure. Post-vaccination
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levels of total antibody can range from 80 to 2,560 HAI, with ranges around 80 
demonstrating need for booster vaccination. In addition to serotyping, canine parvovirus 
PCR was used to rule-in specimens containing CPV nucleic acid and two specimens were 
genotyped.
4.3.3 Nucleic acid isolation in preparation for sequencing
Flocked swabs were used to collect specimens from the rectum of expired canines 
presumed to be related to the outbreak (n=12). Confirmation of parvoviral infection was 
made by rapid fecal enzyme-linked immunosorbent assays (ELISA), necropsy findings 
consistent with acute parvoviral illness (hemorrhagic enteritis with fibrinous serositis), or 
both. Swabs were immediately placed in viral transport medium to stabilize viral 
particles. Representative aliquots (~1mL) of each specimen were centrifuged for 10 
minutes at 15,000 rpm to pellet and discard debris as well as the majority of the host and 
bacterial cells. The supernatant was transferred into a new centrifuge tube and a portion 
of the supernatant (~500uL) was used as the starting material for nucleic acid isolation 
using phenol/chloroform followed by ethanol precipitation as previously described [25, 
26]. DNAse I (New England Biolabs, Inc.) was added to the isolated total nucleic acid to 
remove all genomic DNAs.
4.3.4 Library preparation for sequencing
NEBNext Ultra RNA Library Prep Kit for Illumina (New England Biolabs, Inc) 
was used to construct sequencing library from a starting quantity of 10-200ng of total 
RNA. Individual indexes were used to barcode the fragments and allow for specimen 
pooling. Fragment sizes of ~300bp and larger were selected during AMPure bead cleanup.
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4.3.5 Sequencing and analysis
Libraries were pooled and sequenced using the Illumina MiSeq system and the 
MiSeq Reagent Kit v2 (Illumina) 500-cycle sequencing kit. Paired-end sequencing was 
performed (2 x 251bp) to achieve all base reads available in the 500-cycle sequencing 
format. Read files generated by the sequencer were analyzed by GSNAP reference 
sequence alignment using NCBI Accession NC_001539.1 as the reference genome for 
parvovirus.
4.4 Results
Serological data was difficult to obtain since affected animals would expire before blood 
draws could be acquired. Only three dogs in this data set were tested for canine parvovirus 
antibodies (Parvo6, 7, and 12) each demonstrating low to medium levels of acceptable antibody 
(Table 4.1). PCR was performed on most specimens in this dataset unanimously ruling-in the 
presence of CPV nucleic acid. Three specimens were genotyped, Parvo1 and Parvo2 
(representing the same animal and therefore an opportunity to assess diagnostic reproducibility) 
were typed as a 2/2a virus, and Parvo10 as a 2b virus.
Table 4.2 describes the general sequencing metrics for each specimen tested. The number 
of reads aligning to the canine parvovirus reference sequence (NC_001539.1) ranged from 47 
reads for Parvo11 to 263,625 reads for Parvo9. This type of range can be expected when blindly 
testing clinical specimens and is dependent on sample collection and handling as well as the 
stage of disease presenting in the canine at the time of specimen collection. Read depth ranged 
from 2.2X to 12,381X and genome coverage ranged from 44.8% to 96.5% when aligned to the 
reference genome. Canine parvovirus sequences were heavily masked amongst other sequence 
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data representing an average of 0.95% (range 0.0015% to 6.7%) of the metagenome across all 
specimens sequenced.
Whole genome phylogenetic analysis was performed using CLC Workbench 8 (Figure
4.1) . Parvo1 and Parvo11 samples were not included in this analysis due their lower than 
optimum read depths (<30X). Whole genome sequences from the remaining 10 specimens were 
compared to 13 reference genomes from NCBI representing many variations of subtype 2a and 
2b canine parvoviruses as well as two versions of the attenuated vaccine strain. Phylogenetic 
analysis shows that there were two distinct groups of viruses circulating in the outbreak and 
these groups were directly associated with the geographical location of the animal when it 
became ill. Parvo2, 3, 6, &7 formed a group of somewhat older origin and represented animals 
from Community A. The other grouping of viruses sequenced (Parvo4, 5, 8, 9, 10, & 12) shows 
more recent evolution and were collected from animals approximately 260 kilometers away in 
Community B. Interestingly, Parvo6 was a dog that had been transferred from Community B to 
Community A; however, the sequence data would suggest that the parvovirus infection was 
actually caused by a virus picked up in Community A, not brought in from Community B.
Further analysis of the VP2 protein of each one of these groupings was performed (Figure
4.2) . Parvo6 represented the Community A grouping and Parvo9 represented the Community B 
grouping due to their high genome coverage percentages and read depths (>30X). The nucleic 
acid VP2 sequences for these two viruses were 99.4% similar differing by 10 bases. Five (50%) 
of the base differences resulted in four amino acid sequence differences in the VP2 protein at 
residues 267, 324, 426, and 440. The amino acid difference at residue 426 is a common codon 
affected by polymorphism and is used to diagnostically differentiate CPV-2a and CPV-2b 
viruses with the use of specific sequence-based probes. The amino acid difference at position 
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426 for Parvo6 was asparagine, specific to CPV-2a viruses, and for Parvo9 was aspartic acid 
which is specific to CPV-2b viruses. The amino acid residue at position 297 was alanine for both 
Parvo6 and Parvo9 suggesting they are new strains of CPV-2a and -2b, as described by Decaro et 
al. [27].
4.5 Discussion
The NGS methodology proved to be an effective diagnostic tool for further characterizing 
CPV in rectal swabs of affected canines. Not only was the virus detected, but the RNA for all 
viral proteins was obtained in many cases suggesting that the virus was undergoing active 
replication and causing symptoms. Despite only targeting RNA transcripts, near whole genomes 
were obtained making it possible to construct a phylogenetic tree that demonstrated the presence 
of 2 distinct subtypes of a CPV virus, CPV-2a in dogs living in and around Community A and 
CPV-2b in dogs living in Community B. Similarity of these 2 CPV virus groups to previously 
published CPV sequences as well as the limited presence of protective CPV antibodies in tested 
serum suggest that the outbreak did not involve a novel strain of CPV, but rather exposure in an 
under-vaccinated on unvaccinated, and therefore immunologically naive, dog population.
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-- = Not Tested, HAI = hemagglutination inhibition
Table 4.1: S pecimens and referral results summary







Parvo1 8wk old A -- -- Positive 2/2a
Parvo2 Same animal as Parvo1 (reproducibility 
specimen)
A -- -- Positive 2/2a
Parvo3 8wk old littermate to Parvo1/2 A -- -- Positive --
Parvo4 6 mo. old B -- -- Positive --
Parvo5 1.5 yr. old B -- -- Positive --
Parvo6 2 yr. old, moved from affected 
Community B to Community A
A 160 10 Positive --
Parvo7 6 yr. old, next door neighbor to Parvo6. 
Died within one day of Parvo6.
A 80 <10 Positive --
Parvo8 6 mo. old B -- -- -- --
Parvo9 Unknown B -- -- -- --
Parvo10 5 mo. old B -- -- -- 2b
Parvo11 10 yr. old B -- -- Positive --
Parvo12 20 mo. old B 1,280 <40 Positive --
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Parvol 437.3 1,749,240 277 0.02 13.0 87.8
Parvo2 418.4 1,673,478 1,114 0.07 52.3 93.4
Parvo3 500.0 1,999,824 10,450 0.52 490.8 94.8
Parvo4 924.6 3,698,580 2,418 0.07 113.6 92.4
Parvo5 582.8 2,331,346 44,288 1.90 2,080.0 95.1
Parvo6 630.9 2,523,606 29,789 1.18 1,399.1 96.5
Parvo7 585.3 2,341,324 7,543 0.32 354.3 93.1
Parvo8 509.6 2,038,224 2,744 0.13 128.9 89.1
Parvo9 977.5 3,909,948 263,625 6.74 12,381.4 94.9
Parvo10 348.2 1,392,626 2,906 0.21 136.5 89.4
Parvo11 767.3 3,069,074 47 0.0015 2.2 44.8
Parvo12 435.3 1,741,200 3,439 0.20 161.5 93.5
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Figure 4.1: Phylogenetic tree of clinical specimen isolates in relation to reference sequences of 
canine parvovirus 2a, 2b, and vaccine candidate genomes. Parentheses next to 10 of the 12 
specimens analyzed indicate the age of the canine and kennel origination. Two specimens, 
Parvo1 and Parvo11, are not included in this analysis due to inadequate read depth and 
subsequent insufficient sequence availability. Two major groupings are recognized as distinctly 
2a viruses (Parvo2, 7, 3, 6) and 2b viruses (Parvo10, 9, 5, 4, 8, 12).
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Figure 4.2. Visual depiction of sequence alignment to reference genome, VP2 gene location within the canine parvovirus genome 
and analysis of 18 amino acid positions. Parvo6 and Parvo9 were chosen as representatives of each group of viruses to visualize 
NGS data and varying sequencing depths for each major protein. The VP2 region of each specimen was analyzed at key amino acid 
positions reflecting canine parvovirus subtype. Parvovirus specimens are ordered and categorized as they are depicted in Figure 4.1 
(Phylogenetic tree). “New” canine parvovirus 2a and 2b stem from emerging viruses showing variability at the 426 aa position 
[27].
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The studies included in this thesis were aimed at comparing new technologies to 
conventional methods to help move clinical laboratories forward in their quest to adopt modern 
methods of viral pathogen detection. State and federal regulations, such as CLIA, regulate how 
these assays are validated and implemented for use by clinicians [1]. Published studies, such as 
these, help fulfill components of these validation requirements and can be used by clinical 
laboratories to reduce the time and cost of re-validating the same process in each individual 
laboratory and will also help enhance standardization.
I began by describing the process of validating an assay's analytical sensitivity. The 
issue of whether or not extensive multiplexed respiratory pathogen panels perform at the same 
level of sensitivity when compared to their singleplex counterparts was explored. Chapter 1 
evaluates a commercial assay that utilizes electrochemical detection of PCR amplicons, a novel 
technology produced by GenMark Diagnostics. This multiplex assay was compared to 
established singleplex assays in terms of analytical sensitivity, or lower limit of detection. This 
evaluation assists other clinical laboratories that struggle with making choices between utilizing 
available commercial technology and continuing on with laboratory-developed tests [2]. This 
experiment identified that the analytical sensitivities are challenging to maintain in multiplexed 
systems. In contrast, some assays showed better performance when multiplexed. It was 
determined that the analytical sensitivity of the electrochemical technology showed adequate 
sensitivity for most respiratory viruses tested except for the generic influenza A assay. Clinical 
laboratories are dependent on sensitive generic influenza A assays for screening clinical 
specimens prior to subtyping. Because the screening assay was found to be less sensitive, false 
negativity may be an issue. This is especially concerning for influenza surveillance centers aimed 
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at targeting the occurrence of influenza A viruses due to its history of causing devastating 
pandemics across species. Although this technology proved to be comparable in terms of the 
sensitivity of most respiratory viruses tested, users should caution the lack of sensitivity for 
influenza A detection when compared to singleplex assays.
Chapter 2 aims at measuring the positive predictive value (PPV) of an assay performed 
using new technology when imposed on a population of low disease prevalence, for example, 
when conducting HIV surveillance in Alaska. This is an important topic because assays, in 
general, perform poorly in terms of false positivity when used in populations with limited 
disease. An example of an assay evident of this phenomenon is rapid tests for influenza being 
widely used in hospitals and clinics. When influenza prevalence is low in a population, false 
positivity occurs more often on rapid tests. On the other hand, when influenza prevalence is high 
like in the middle of respiratory virus season, the rate of false positivity goes down. In terms of 
HIV, the assay examined uses multiplex flow immunoassay technology marketed by BioRad 
Laboratories to broadly capture the presence of HIV-1 and HIV-2 viruses and/or antibodies in a 
patient's serum. It was determined that the PPV was acceptable (62.9%) when compared to other 
assays currently on the market. Also, it should not be understated that this new technology offers 
broad detection of HIV viruses while simultaneously providing differentiation of which type of 
virus and/or antibody is present. This can be extremely advantageous for interpreting test 
outcomes and relating it to a patient's HIV status, even when faced with less than desirable false 
positivity rates.
Chapter 3 describes the potential of using NGS compared to conventional methods for 
virus detection. Using turnaround time and result outcomes as an indicator of clinical utility 
clearly reveal that NGS is capable of fully characterizing viral genomes, even when heavily 
122
masked in the background of the specimen metagenome [3]. Full characterization not only 
identified the isolate of the viral species but also identified known antiviral resistance markers, 
both of which have significant clinical impact on disease diagnosis and treatment. Many 
applications in clinical laboratories using NGS are focused on targeted approaches to try to limit 
the amount of unwanted metagenomic data [4, 5]. The experiment described in Chapter 3 is the 
first of its kind describing the true fraction of targeted pathogen within the metagenome, without 
utilizing enrichment techniques, demonstrating the true scarcity of pathogenic nucleic acid in 
clinical specimens and the sensitivity potential of massively parallel sequencing.
Chapter 4 demonstrates the ability of NGS to not only detect and fully characterize a 
virus associated with an outbreak, but to investigate the outbreak source in detail. In this 
example, rectal swabs were used to sequence two strains of canine parvovirus, occurring 
simultaneously in two different geographical locations. This study helped distinguish these 
viruses as similar to vaccine strains, not novel strains as previously assumed due to the amount 
of dog deaths associated with the outbreak. Phylogenetic evaluation of these strains in 
combination with serological data helped drive the conclusion that these dogs were most likely 
experiencing a disease outcome associated with un- or under-vaccinated dog populations [5-7]. 
This type of epidemiological analysis can be extrapolated to human viral pathogen outbreaks in 
order to associate cases of infection to their potential source, drive better outbreak interventions, 
and diminish community panic [6].
In conclusion, this thesis examines new technologies designed to detect and characterize 
pathogenic viruses. Some technologies, like those offered by companies like GenMark and 
BioRad, are well-developed and provide current benefit to the health of patients. Others, like 
next generation sequencing methods, require much more validation before becoming a routine 
123
method in clinical laboratories. However, successful use of next generation sequencing methods 
in context of an infectious disease laboratory may better prepare clinical labs in their role in 
precision medicine, the long-term research goal of the National Institute of Health which focuses 
on understanding individual variability in disease prevention, care, and treatment [8]. Infectious 
disease laboratories should strive to adopt new, target-independent technologies to expand 
pathogen detection to support these types of initiatives.
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Multiplex PCR Platform for Detecting Respiratory Viruses5
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Comparison between Singleplex Real-Time PCR and a Multiplex PCR Platform for Detecting Respiratory 
Viruses. PLOS ONE, 2015. 10(11): e0143164.
Abstract
Multiplex PCR methods are attractive to clinical laboratories wanting to broaden their 
detection of respiratory viral pathogens in clinical specimens. However, multiplexed assays must 
be well optimized to retain or improve upon the analytic sensitivity of their singleplex 
counterparts. In this experiment, the lower limit of detection (LOD) of singleplex real-time PCR 
assays targeting respiratory viruses is compared to an equivalent panel on a multiplex PCR 
platform, the GenMark eSensor RVP. LODs were measured for each singleplex real-time PCR 
assay and expressed as the lowest copy number detected 95-100% of the time, depending on the 
assay. The GenMark eSensor RVP LODs were obtained by converting the TCID50/mL 
concentrations reported in the package insert to copies∕μL using qPCR. Analytical sensitivity 
between the two methods varied from 1.2-1280.8 copies∕μL (0.08-3.11 log differences) for all 
12 assays compared. Assays targeting influenza A/H3N2, influenza A/H1N1pdm09, influenza B, 
and human parainfluenza 1 and 2 were most comparable (1.2-8.4 copies/μL, <1 log difference). 
Largest differences in LOD were demonstrated for assays targeting adenovirus group E, 
respiratory syncytial virus subtype A, and a generic assay for all influenza A viruses regardless 
of subtype (319.4-1280.8 copies/μL, 2.50-3.11 log difference). The multiplex PCR platform, the 
GenMark eSensor RVP, demonstrated improved analytical sensitivity for detecting influenza
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A/H3 viruses, influenza B virus, human parainfluenza virus 2, and human rhinovirus (1.6-94.8 
copies∕μL, 0.20-1.98 logs). Broader detection of influenza A/H3 viruses was demonstrated by 
the GenMark eSensor RVP. The relationship between TCID50/mL concentrations and the 
corresponding copy number related to various ATCC cultures is also reported.
Introduction
Multiplex PCR methods, those that target more than one pathogen in a single test, benefit 
diagnostics in a clinical laboratory due to their ability to detect and rule-out many related 
pathogens in the same amount of time. New and improved workflow designs make it possible for 
laboratories with varied molecular technical ability to implement multiplex PCR platforms.
The Respiratory Viral Panel (RVP) manufactured by GenMark Diagnostics, Inc. is a 
multiplex PCR panel that detects the amplification of various viral gene fragments 
electrochemically. Nucleic acids from targeted viral pathogens are amplified using a multiplex 
PCR reaction followed by denaturation of the double stranded molecules into single 
oligonucleotide strands using exonuclease. Once the amplicons are in a single-stranded state, 
they are hybridized to a complementary virus-specific signal probe tagged with ferrocene, a 
reducing agent. This hybridized molecule is then exposed to another sequence-specific probe 
which is bound to a solid phase, a gold electrode. Upon application of a low voltage current, the 
hybridized molecule bound to this solid phase brings the ferrocene in close proximity to the gold 
electrode where reversible electron transfer can occur and the resulting current can be measured. 
Viral pathogenic nucleic acid can be detected with confidence when measurements are at or 
exceed 3 nanoamps (nA) on the GenMark XT-8 instrument. The GenMark eSensor RVP has 
been shown to be highly comparable to other multiplex PCR platforms as well as singleplex real­
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time PCR in terms of diagnostic sensitivity and specificity[1,2], which measures the level of 
correlation between two methods. In this experiment, the primary interest is the analytical 
sensitivity of the PCR assays, or the minimum detectable concentration of the target. The 
GenMark eSensor RVP LODs as determined by the manufacturer are compared to singleplex 
real-time PCR assay LODs determined by our laboratory and expressed as lowest copy number 
reliably detected 95-100% of the time.
Limit of detections for FDA-approved clinical assays, including those described in the 
GenMark eSensor RVP package insert, are commonly expressed as 50% tissue culture infectious 
dose per milliliter, or TCID50/mL. Although this is a standard practice, other quantification 
methods such as real-time PCR are also reliable and may be able to more precisely describe 
quantities of viral particles with or without TCID50/mL calculations as a reference[3-6]. Since 
the LODs for the GenMark RVP assays are expressed exclusively as TCID50/mL 
concentrations, these values needed to be converted to copy number per μL in order to meet our 
goals of comparing analytical sensitivity as lowest copy number. The LODs of each GenMark 
RVP assay were not re-established in our laboratory. Instead, manufacturer established 
TCID50/mL values were converted to copy number using quantitative real-time PCR (qPCR). 
Performing this conversion also provided an opportunity to view the relationship between 
TCID50/mL and copy number and relate this information to various virus-infected ATCC cell 
cultures.
The respiratory assays evaluated in this experiment target the following virus species: 
influenza A virus (InfA/H3N2 and InfA/H1N1pdm09), influenza B virus (InfB), human 
respiratory syncytial virus (RSV), human parainfluenza virus (hPIV 1, 2, and 3), human 
adenovirus (Adeno), and human rhinovirus (hRV). The multiplex GenMark eSensor RVP assays 
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were able to further distinguish human adenoviruses as belonging to subgenera C or E and 
respiratory syncytial viruses as belonging to subgroup A or B, unlike the singleplex real-time 
PCR assays that were designed to detect human adenovirus and respiratory syncytial virus 
universally across all subgroups. A generic influenza A virus assay, one that targets a conserved 
region of all influenza A viruses regardless of strain, was also evaluated.
Methods and Materials
Clinical specimens
Clinical specimens used in this study were de-identified. The University of Alaska 
Fairbanks Institutional Review Board (IRB) has determined that the proposed research qualifies 
for exemption from the requirements of 45 CFR 46 (Approval number: 667418-1). 
Preparation of standard materials
Specific plasmids were created for each real-time PCR assay by ligating single copies of 
the diagnostic amplicon onto vectors (pCR 2.1 or pCR4, Invitrogen) and amplifying via TOPO 
cloning (Invitrogen). Transformant E.coli competent cells were extracted using a 
phenol/chloroform mixture and the presence of viral-specific inserts was verified by sequencing 
(Elim Biopharmaceuticals, Inc.).
Plasmid concentrations were calculated by performing two quantification methods: 1) 
fluorometry specific to double stranded DNA (Qubit 2.0, dsDNA br Assay Kit, Invitrogen) and 
2) pixel intensity measurements using the ImageJ application[7]. Using ImageJ, the pixel 
intensity of linearized plasmid DNA gel bands could be interpolated into a standard curve 
consisting of 1KB ladder dilutions (New England Biolaboratories) to predict quantities of 
unknown bands on the gel. Plasmid DNA was linearized using restriction enzyme NcoI (New 
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England Biolabs) prior to gel electrophoresis. These quantification strategies were chosen to 
focus on the DNA of interest and to help exclude possible quantification pitfalls of over or 
underestimating DNA concentrations. Used in combination, these methods accounted for 
contaminating RNA (fluorometry specific for DNA only) as well as contaminating DNA as seen 
as different sized bands on the gel which could be excluded by only measuring the pixel intensity 
of gel bands of expected size (~4KB).
Differences between the two quantification methods ranged from 0.2 to 5.4 ng∕μL
(average 2.6 ng∕μL ± 1.8). Final concentrations were calculated by rounding the average of the 
two methods to the nearest 2.5ng∕μL. The weight of each plasmid was calculated using Geneious 
(v.8.1.3), using the known sequence of the vector in addition to the confirmed sequence of the 
insert. Final copy numbers (per μL) were calculated by dividing the plasmid weights (ng/copy) 
into the concentrations of each plasmid (ng∕μL). Results of the quantification methods and 
downstream calculations are shown in Table A.1.













Adeno pCR2.1 8.0 7.8 7.9 ± 0.2 7.5 4.17 x 10-9 1.80 x 109
InfA pCR 2.1 10.1 11.5 10.8 ± 1.0 10 4.14 x 10-9 2.42 x 109
InfA/H3N2 pCR4 14.5 9.1 11.8 ± 3.8 10 4.37 x 10-9 2.29 x 109
InfA/H1N1pdm09 pCR2.1 11.1 11.8 11.5 ± 0.5 10 4.15 x 10-9 2.41 x 109
InfB pCR4 26.0 31.1 28.6 ± 3.6 30 4.17 x 10-9 7.19 x 109
hPIV-1 pCR4 13.2 8.7 9.5 ± 2.0 10 4.32 x 10-9 2.31 x 109
hPIV-2 pCR4 7.4 6.7 7.0 ± 0.5 7.5 4.15 x 10-9 1.81 x 109
hPIV-3 pCR4 38.8 35.0 36.9 ± 2.7 35 4.19 x 10-9 8.35 x 109
RSV pCR4 5.1 6.2 5.7 ± 0.8 5 4.17 x 10-9 1.20 x 109
hRV pCR4 32.7 29.8 31.3 ± 2.1 30 4.27 x 10-9 7.03 x 109
*Weight/copy was calculated using Geneious (v.8.1.3) which considers the exact sequence of the 
plasmid.
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Determination of singleplex real-time LOD
Plasmid DNA was serially diluted to produce eight (8) test concentrations ranging 
between 1 copies/μL and 1250 copies/μL, depending on the assay. This narrow range was chosen 
to identify the lowest potential copy number able to be detected repeatedly, but keep it above 
theoretical limitations of real time PCR, <3 copies (0.6 copies/uL when using 5uL per 
reaction)[8]. Seven (7) replicates were tested at each concentration. This process was repeated 
twice, once using nuclease-free water as the diluent background for the plasmids to assess basic 
analytical sensitivity and once using total nucleic acid extract (TNA) as background for the 
plasmids to simulate real clinical matrices. TNA was isolated from clinical specimens using the 
easyMAG total nucleic acid automated extractor (Biomerieux). A total of 200μL of the clinical 
specimen was extracted and final eluate volumes were 60μL. TNA from clinical specimens were 
screened by PCR, and only those that demonstrated the absence of target DNA or RNA were 
qualified to be pooled as clinical background diluent.
Primers and probes used in the laboratory-developed real-time PCR assays have been 
previously described[9,10]. Influenza assays were performed using Invitrogen Superscript III 
reagents and all other assays were performed using Ambion AgPath ID reagents. For assays 
using the Invitrogen reagents, the following PCR thermal cycling profile was used; 50°C hold for 
30 minutes, 95°C hold for 2 minutes, and 45 cycles of 95°C for 15 seconds then 55°C for 30 
seconds. For assays using the Ambion reagents, the following PCR thermal cycling profile was 
used; 45°C hold for 10 minutes, 95°C for 10 minutes, and 45 cycles of 95°C for 15 seconds then 
55°C for 1 minute. Reactions were tested using ABI 7500Dx thermal cyclers (Life 
Technologies).
132
Negative controls consisted of no template control replicates (NTC, n = 3) and diluent 
blank replicates, made up of water or TNA diluent (n = 7) to assess contamination. Positive 
reactions were defined as those amplification curves that produced cycle threshold (Ct) values at 
or below 40 cycles. The LOD was chosen as the concentration that demonstrated a percentage of 
positivity over all replicates at a particular dilution. The percentage of positivity was chosen 
using those that were set by the manufacturer for each matching GenMark RVP assay. All but 
three assays were set by the manufacturer below 100% positivity (InfA/H1N1pdm09, RSVA, 
and hRV assays only); therefore, the LOD for these particular singleplex assays were estimated 
using probit analysis to match these probabilities for comparison purposes[11]. Final LODs were 
expressed as a concentration, copies∕μL (Table A.2).
Table A.2: LOD comparison summary
Singleplex Real-time PCR Multiplex PCR GenMark 
eSensor RVP
Lowest copies/ uL detected










Adeno C 100% 1.6 4 110.4 ± 8 108.8 2.04
Adeno E 100% 1.6 4 390.4 ± 45.4 388.8 2.59
InfA 100% 5.4 21.2 1286.2 ± 23.2 1280.8 3.11
InfA/H3N2 100% 10.6 21.2 <2.2 8.4 0.92*
InfA/H1N1 97.5% 7 7 10 ± 4.4 3 0.48
InfB 100% 2.6 53.2 1 ± 2.8 1.6 0.20*
hPIV-1 100% 1 1 <2.2 1.2 0.08
hPIV-2 100% 5.4 2.2 1.6 ± 0.6 3.8 0.58*
hPIV-3 100% 2.2 1 134.8 ± 8.4 132.6 2.12
RSVA 97.5% 6.8 3.6 326.2 ± 22.8 319.4 2.50
RSVB 100% 10.6 5.2 120.2 ± 8.6 109.6 2.04
hRV 95% 111.8 82.4 <17 94.8 1.98*
*lower LOD demonstrated for the multiplex assay; 5μL used in each reaction. Adenovirus and RSV assays were 
not differentiated with the singleplex real-time PCR assay, although RSV assays were calculated differently based 
on %pos to be compared. The TCID50/mL concentration for InfA/H3, HPIV 1, and hRV exceeded the detection limit 
on the qPCR assay. Copy number difference was calculated by subtracting the lowest copies/ μ L detected with 
clinical background on the singleplex assays from the average copies/ μ L equivalent converted from TCID50/mL.
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Conversion of TCID50∕mL concentrations to copies∕μL
Cell cultures with known TCID50/mL quantities of target viruses (ATCC) were used to 
estimate the LOD for the GenMark RVP assay. Cultures were stored in liquid nitrogen until they 
were extracted using the easyMAG total nucleic acid automated extractor (Biomerieux). A total 
of 200μL of the TCID50/mL culture was extracted and final eluate volumes were 60μL. Purified 
nucleic acid was stored at -80°C until tested by quantitative real time PCR (qPCR).
Using quantified plasmids containing inserts specific to each assay, ten-fold dilutions 
were prepared covering 101 to 106 copies∕5μL. Each dilution was tested in triplicate to create a 
standard curve. All qPCR assays utilized a sequence-specific hydrolysis probe with the exception 
of the H3 due to sequence incompatibilities with the ATCC strain being analyzed (see results). In 
this case, a SYBR Green assay (GoTaq, Promega) with new primers were designed to target this 
specific strain of Influenza A/H3. Alongside the standard curve, dilutions of the isolated nucleic 
acid derived from the ATCC cultures were tested in triplicate at dilutions that would include 
reported GenMark eSensor RVP LOD TCID50/mL values. As with the singleplex real-time PCR 
assays, reactions were tested on ABI 7500Dx thermal cyclers (Life Technologies) and standard 
curves and associated unknown quantities were calculated using ABI 7500 v2.3 software. The 
copy number equivalents for each GenMark eSensor RVP assay's LOD is shown in Table 2. The 
relationship between copy number and TCID50/mL for each ATCC culture tested is shown in 
Table 3.
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LOD for GenMark 
eSensor assays 
(TCID50/mL)
VR-1 Adenovirus Type 1 (C) 7 ± 1 8.89 x 101
VR-1572 Adenovirus Type 4 (E) 124 ± 14 1.58 x 101
VR-547 Influenza A/H3 (Aichi) 0.01 ± 0 1.58 x 103
VR-1736 Influenza A/H1N1 2,381 ± 1,048 1.05 x 10-1
VR-101 Influenza B 16 ± 44 3.16 x 10-1
VR-94 Human Parainfluenza Virus Type 1 (C35) 391 ± 0 2.81 x 10-2
VR-92 Human Parainfluenza Virus Type 2 (Greer) 0.03 ± 0.01 2.81 x 100
VR-93 Human Parainfluenza Virus Type 3 (C243) 24 ± 1 2.81 x 101
VR-1540 Respiratory Syncytial Virus (A2) 6 ± 1 2.81 x 100
VR-955 Respiratory Syncytial Virus (B9320) 38 ± 3 1.58 x 100
VR-483 Rhinovirus 3 FEB 53,797 ± 0 1.58 x 10-3
SD = standard deviation, SD could not be calculated for VR-547, VR-94, and VR-483 since the 
TCID50/mL concentration exceeded the detection limit on the qPCR assay.
Results
Ten singleplex real-time PCR assays were compared in terms of analytical sensitivity to 
twelve multiplex assays on the GenMark eSensor RVP. This difference stems from the fact that 
the singleplex real-time PCR assays are not designed to distinguish between different subgenera 
of human adenovirus or different subtypes of respiratory syncytial viruses (RSV), while the 
GenMark eSensor RVP differentiates between human adenovirus C and E as well as RSV 
subtype A and B. Thus, two additional assays were evaluated for the GenMark eSensor RVP. 
Analytical sensitivity was expressed as lowest copies∕μL concentration for all assays.
The Genmark eSensor RVP capable of distinguishing between different subgenera of 
adenoviruses (C vs. E) demonstrated less analytical sensitivity than the generic singleplex real­
time PCR assay targeting all adenoviruses, differing by 108.8 copies∕μL (2.04 log difference), 
and 388.8 copies/μL (2.59 log difference), respectively. The difference in sensitivity may be due 
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to slight variations in the targeted priming region. The singleplex real-time PCR assays use 
primers designed to anneal highly conserved sequences within the hexon-coding region in order 
to target all adenoviruses, whereas the GenMark eSensor RVP assays use subgenera-specific 
hexon primers to make possible the distinction between adenovirus subgenera C and E. Upper 
respiratory tract infections associated with adenovirus C viruses infect more than 80% of the 
population early in life[12]; however, infections with the adenovirus E (serotype 4) can prove to 
be more severe and even fatal for people living in close quarters, such as military recruits[13]. In 
terms of surveillance, differentiation of virus subgenera within a population may be clinically 
useful, regardless of lost sensitivity.
Similarly, the singleplex real-time PCR assay generically targeting respiratory syncytial 
viruses also demonstrated better sensitivity than the GenMark eSensor RVP assays which are 
capable of distinguishing between subtypes A and B (319.4 copies∕μL, 2.50 log difference and 
109.6 copies∕μL, 2.04 log difference, respectively). Respiratory syncytial viruses in subtype A 
are thought to be more prevalent and virulent than those in subtype B[14]. Subtyping respiratory 
syncytial virus may be clinically beneficial when surveilling populations that experience high 
hospitalization rates associated with the virus, such as Native Americans living in southwest 
United States and Alaska[15].
Analytical sensitivity of assays targeting the current circulating strains of influenza A 
viruses in the human population, H3N2 and H1N1pdm09, were highly comparable between the 
singleplex real-time PCR and multiplex GenMark eSensor RVP assays (8.4 copies∕μL, 0.92 log 
difference and 3 copies∕μL, 0.48 log difference, respectively). Comparing the LOD between the 
influenza H3N2 assays proved to be the most challenging. When converting TCID50/mL 
concentrations to copies/μL. using qPCR, it was determined that this particular culture contained 
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an uncommon virus, an Aichi strain (A/Aichi/2/35) circa 1968 (ATCC) and therefore could not 
be amplified using the singleplex real-time PCR assay, which is designed to detect current 
influenza A/H3N2 virus strains. However, it was repeatedly detected using the GenMark eSensor 
RVP. This finding suggests that the eSensor RVP is capable of detecting a broader range of 
Influenza A/H3N2 strains while maintaining a comparable analytic sensitivity to that of its 
singleplex real-time PCR counterpart.
The greatest difference measured between analytic sensitivities was seen with the generic 
influenza A assay showing a 3.11 log difference in LOD (1280.8 copies/μL difference). Because 
the LOD for the generic influenza A assay is much higher than the subtype assays (as described 
above) for the multiplex GenMark eSensor RVP, difficulty in result interpretation from 
specimens with low influenza A virus titers is likely, since subtypes (H3N2 or H1N1pdm09) 
have a lower LOD than the generic influenza A assay (e.g. + H3N2,—influenza A). The 
performance of the generic influenza A assay is an important surveillance tool for tracking 
genetic changes among influenza A viruses. For instance, specimens demonstrating positivity for 
influenza A using this generic, highly conserved matrix-coding region may not subtype using the 
H3N2 or H1N1pdm09 assays, which may indicate that the virus is novel and worthy of alerting 
public health authorities. In contrast, the influenza B assays were shown to be highly comparable 
between the singleplex and multiplex assays, with a difference of only 1.6 copies/μL (0.20 log 
difference).
Human parainfluenza 1 assays were highly comparable (1.2 copies/μL, 0.08 log 
difference). Human parainfluenza 2 assays demonstrated improved sensitivity on the multiplex 
GenMark eSensor assay (3.8 copies/μL, 0.58 log difference). Human parainfluenza 3 assays 
demonstrated the largest difference in analytical sensitivity among the human parainfluenza 
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serotypes, demonstrating a 2.12 log improvement in detectability when using the singleplex real­
time PCR assay (132.6 copies∕μL difference).
Five of the twelve GenMark eSensor RVP assays matched (<1 log difference in
copies/μL) the LOD of the real-time singleplex PCR assay targets in this study (Table 2). These 
include influenza A/H3N2, influenza A/H1N1pdm09, influenza B, and human parainfluenza 1 
and 2. Six of the twelve assays compared showed greater sensitivity using the real-time 
singleplex assays. These include the adenovirus assays (C & E), influenza A, human 
parainfluenza 3, and RSV (A & B). The GenMark eSensor human rhinovirus assay demonstrated 
the biggest difference in terms of improved detection when compared to its singleplex 
counterpart (94.8 copies/μL, 1.98 log difference, 95% positivity).
The number of genome copies per TCID50/mL value was highly variable ranging from 
0.01 to 53,797 (Table 3). LODs set at higher TCID50∕mL concentrations (102-103) 
corresponded to stock cultures with lower copy numbers (0.01 to 6 copies). LODs set at in the 
mid-range TCID50/mL concentrations (101 to 10-1) corresponded to stock cultures with 
variable copy numbers per TCID50/mL (7-2,381 copies). LODs set at lower TCID50/mL 
concentrations (10-2-10-3) corresponded to stock cultures with somewhat higher copy numbers 
per TCID50/mL (391-53,797 copies).
Conclusion
Multiplex PCR applications benefit diagnostics in a clinical laboratory due to their ability 
to detect and rule-out many related pathogens in a single reaction, reducing tech-time by more 
than 3 hours for a panel of 10 viruses[1]. However, multiplex PCR platforms continue to carry 
higher overall costs. Analytic sensitivity, or the lowest possible concentration necessary to 
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produce a reliable result, is an important parameter to consider when replacing singleplex real­
time PCR assays with multiplex PCR platforms evolving from newer, more expensive 
technologies. This experiment aims at finding a method in which to compare LODs of various 
assays using copy number as the unit of expression.
Choosing a 2.5 log difference to express considerable loss in sensitivity, the multiplex 
PCR strategy in combination with the GenMark eSensor technology demonstrates a considerable 
loss in sensitivity for three of the twelve assays assessed. Two of the assays were adenovirus E 
and respiratory syncytial virus subtype A. Although sensitivity is reduced, further 
characterization of viruses in clinical specimens may be of greater clinical importance, especially 
when particular subtypes are known to be more virulent in the population as is the case with 
adenovirus serotype 4 (subgenera E) and respiratory syncytial virus subtype A in particular 
populations.
The third assay demonstrating considerable loss in sensitivity was for the generic 
influenza A assay. Clinical laboratories, especially those directly related to public health 
surveillance, may need to consider the significance of this reduced sensitivity since it is 
commonly used to rule out novel influenza. Better analytic sensitivity was achieved using 
singleplex real-time PCR, which indicates that influenza A can be detected in clinical specimens 
even at low titers using this method. Specimens collected from patients that are suspected to have 
influenza infections that test negative on the GenMark eSensor RVP may need to be tested by 
more sensitive methods to rule out cases of novel influenza.
Expressing LOD in units that can be comparable across methodologies can prove to be 
difficult experimentally. TCID50/mL measurements can vary depending on how these cultures 
are handled in the laboratory in regards to preserving the concentration of infectious virus 
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particles for purposes of experimentation and quantity comparisons. Molecular detection 
strategies used in clinical laboratories are non-discriminating when identifying infectious or non- 
infectious viruses. PCR methodologies used to detect viral targets in clinical specimens do not 
provide information regarding the viability of the virus and, therefore, every detection may not 
point to a causative agent of disease. Other complicating factors to consider when interpreting 
PCR results are that patients can be asymptomatic carriers or may be exhibiting evidence of a 
past infections. Viral copy numbers provide an estimate of the number of virus particles in a 
given volume, but in our experiment, they did not correlate well with the number of infectious 
particles. To test the analytical sensitivity of a PCR-based methodology, it is important to 
understand that the intent of the assay is to detect any genome copy targeted by the designed 
primers, whether these be from infectious or non-infectious virus particles.
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Appendix B
Application of next generation sequencing for the detection of human viral pathogens in clinical 
specimens6
6 Original publication as cited: Parker J, Chen J. Application of next generation sequencing for the detection of 
human viral pathogens in clinical specimens. Journal of Clinical Virology. 2016; 86:20-26
Abstract
Background: Next generation sequencing (NGS) is a new technology that can be used for broad 
detection of infectious pathogens and is rapidly becoming an essential platform in clinical 
laboratories. It is not known how NGS will displace or enhance gold standard methodologies in 
infectious disease diagnosis.
Objectives: To investigate the feasibility and application of NGS technology in public health 
laboratories and compare NGS technology with conventional methods.
Study Design: Illumina MiSeq system was used to detect viral pathogens alongside other 
conventional virology methods using typical clinical specimen matrices. Sixteen clinical 
specimens and two CDC proficiency panels containing seventeen specimens were analyzed. 
Results: Known pathogenic viral nucleic acid was positively identified in all clinical specimens, 
correlating and building upon results obtained by more conventional laboratory methods. 
Sequencing depths ranged from 0.008X to 319 and genome coverage ranged from 0. 6% to 
99.9%. To substantiate the described methods used to analyze data derived from clinical 
specimens, the results of a clinical proficiency panel are also presented.
Discussion: Our results reveal true scarcity of known pathogenic viral nucleic acids in clinical 
specimens. NGS outperforms more conventional detection methods in this study by turnaround 
time as well as the improved depth of knowledge in regards to serotyping and drug resistance.
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Background:
Methodologies to detect pathogenic viruses in clinical specimens have transitioned from classic 
cell culture and antibody-antigen techniques to more sensitive molecular methods such as 
polymerase chain reaction (PCR). The targeted nature of these methodologies inhibit their 
ability to accommodate the true diversity of human pathogens in a clinical specimen, especially 
viruses [1]. Next generation sequencing (NGS) technologies are quickly demonstrating their 
ability to provide broad detection of infectious agents in a target-independent manner [2-7]. 
NGS has many advantages beyond the improved detection of all suspected, unsuspected, or even 
novel pathogens in a clinical specimen [8]. Familiarization with pathogen genomic sequences 
within clinical specimens enhances our understanding of infectious disease through further 
discovery of pathogen variability and genotyping [9-13], drug resistance or response to therapy 
[14-16], vaccine development and efficacy monitoring [17], and further characterization of the 
metagenome [18, 19]. The use of NGS for routine use in clinical diagnostics is emerging with its 
own set of limitations and challenges [13, 20]. Focusing on viruses of public health importance, 
we compared the performance of NGS alongside other more common viral detection 
methodologies.
Objectives
• To investigate the feasibility and application of NGS technology in public health 
laboratories and compare NGS technology with conventional methods
• To examine genome coverage and read depth of viral nucleic acid in various types of 
clinical specimens.
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• To address the need for acceptability standards when using NGS due to the true scarcity of 
pathogenic viral nucleic acids in some clinical specimens.
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Study Design:
Specimens: Sixteen previously tested clinical specimens, swab and serum specimens, were 
provided by the Alaska State Virology Laboratory in Fairbanks, Alaska. Two proficiency panels 
with a combined seventeen specimens for detecting antiviral resistance markers in the 
neuraminidase gene of influenza A virus were also tested as a quality indicator of our process. 
Proficiency specimens consisted of cultured Madin-Darby Canine Kidney Epithelial (MDCK) 
cells infected with influenza A virus.
Construction of sequencing library: Nucleic acid was isolated from 500μL of the original 
clinical specimen using phenol/chloroform followed by ethanol precipitation. DNA or RNA 
molecules were selected for by using DNase I (serum and proficiency specimens) or RNAse 
(swab specimens, with the exception of the influenza specimens). Quantity was evaluated using 
the Qubit instrument (Thermo Fisher Scientific) and the Agilent Bioanalyzer. The Nextera DNA 
Specimen Preparation protocol (Illumina) and the NEBNext Ultra RNA Library Prep Kit 
protocol (New England Biolab) were followed to prepare sequencing libraries.
Sequencing and data analysis. Libraries underwent paired-end sequencing on the Illumina 
MiSeq using a v.2 500-cycle kit. Read files were imported into Pathseq™Virome for reference 
genome identification. Alignments to the identified viral genome sequence(s) were performed 
by Sequencher (v5.1) in addition to an external tool, Genomic Short-read Nucleotide Alignment 




NGS for detecting clinical adenovirus infections
Adenoviruses are important to characterize in the laboratory since some serotypes are 
more commonly associated with outbreaks, severe pneumonia, and possibly cancer such as 
serotypes 14, 55, and 12 [25]. Two infections were able to be diagnosed and further 
characterized using NGS (Figure 1).
Figure B.1. Comparison of NGS and conventional virology assays for detecting adenovirus 
infection. Pie charts further describe sequence data as well as storage needed as compressed files 
(.gz). Percentage refers to the proportion of the total reads represented by the isolate reads. 
Exploding bar graph shows the percentage of the full genome that was identified by the reported 
number of reads.
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NGS for detecting clinical herpesvirus infection
The results of three specimens are compared, two are clinical specimens and one is a 
cultured clinical isolate (Figure 2). As expected, the overall proportion of viral reads is much 
higher when sequencing clinical isolates (>15%) when compared to raw clinical materials 
(<1%).
Results were concurrent amongst all methods; however, the result obtained by 
conventional methods for the nasopharyngeal swab were not definitively concurrent. Sequence 
analysis identified human herpesvirus 5 strain HAN2 (JX512200), same as conventional 
methods, but by only 10 reads. Torque teno virus isolate US32 (AF122921) was more 
definitively identified. Surveillance for torque teno viruses is not common since they are thought 
to be ubiquitous in humans and lack concrete disease association [27]. Nevertheless, NGS alone 
could not definitively identify actively replicating human herpesvirus 5, like viral culture could 
over 14 days, due to such low representation of viral total nucleic acid overall in the original 
clinical specimen (0.0005%).
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Figure B.2. Comparison of NGS and conventional virology assays for detecting herpesvirus 
infection.
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Further characterization of viral hepatitis C and G
Methodologies to compare NGS's ability to detect hepatitis C was not evaluated, but 
rather sequence analysis was performed to discover how NGS could be used to further 
characterize the virus. Specimens were all positive for genotype 1a HCV and specific isolates 
were identified by PathSeq™Virome (Figure 3).
New direct acting antiviral therapies have been designed to target and impair the 
functions of non-structural proteins, NS3/4A, NS5A, and NS5B. In response, breakthrough 
mutations in these particular viral genes have demonstrated antiviral resistance to certain HCV 
antiviral therapies [29-33]. Figure 3 summarizes resistance data obtained by NGS for each 
protein targeted as well as the antiviral therapies that are associated. Isolate identified as V60- 
like was found to have one mutation affecting susceptibility to NS5A-inhibitors (M38V) and 2 
mutations affecting susceptibility to N3/NS4-inhibitors (T54S and Q80K). Three other isolates, 
identified as V179-, V173-, and V269-like, each showed 1 mutation leading to reduced 
susceptibility to N3/NS4-inhibitors (Q80K).
Figure 3 also shows that hepatitis G virus (HGV) isolates were simultaneously identified 
in three of the five specimens tested (60%). It is known that HGV infections are closely 
associated with HCV infections due to parallel routes of transmission [34, 35]. Although not 
commonly practiced, more thorough surveillance of HGV infections in humans may be 
necessary due to indications that it is a significant player in determining the course and prognosis 
of other diseases such as HIV, HCV, and even diseases of the brain [5, 35]. NGS is an 
appropriate method in which to detect and characterize both HCV and HGV viruses in parallel.
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Figure B.3. Detection and characterization of hepatitis C and G viruses in 5 different sera using NGS.
Three groups of antiviral drugs are shown targeting proteins NS5A, NS5B, and N3/N4A. Isolates (i.e. V60, V179) should be 
thought of as V60-like or V179-like, as identified by sequence analysis. Blackened columns of amino acids indicate that one or 
more isolates were found to have mutations at those positions associated with antiviral resistance.
Antiviral resistance of influenza viruses in clinical specimens
Data is provided for six nasopharyngeal swab specimens containing influenza viruses 
tested by PCR methods and NGS (Figure 4). NGS results detected regions of the genome 
attributed to antiviral drug resistance, as previously described [36-38]. Genome-wide diagrams 
of alignments to reference genomes produced by Tablet illustrate the various coverages obtained 
for each clinical specimen (Figure 4). Large variations amongst the results are attributed to the 
quantity and quality of virus in the original clinical specimen since enrichments techniques such 
as filtration or centrifugation were not used. Identification of polymorphisms, especially those 
occurring at specific positions of the neuraminidase gene, may indicate various levels of antiviral 
resistance to neuraminidase inhibitors and serves as an important piece of information in terms of 
influenza surveillance. No variants were detected amongst the clinical specimens analyzed (all 
wild type). For influenza A/H3, one specimen was missing sequence information was for one 
amino acid motif, 119. For influenza B, one specimen was missing the entire NA gene and could 
not be analyzed.
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Figure B.4. Antiviral resistance characterization of influenza viruses using NGS 
Genome-wide views as produced by Tablet. Figure is split into 3 influenza virus types, A/H3N2 
viruses, A/H1N1 viruses, and B viruses. Whole genome metrics are compared to those obtained 
for the NA gene only. Segment 6, the NA gene, is boxed out for each specimen and exploded 
into a table describing the outcomes of antiviral resistance analysis performed for each type of 
influenza virus.
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Results of a proficiency panel intended for laboratories using pyrosequencing methods 
are compared to those obtained by NGS (Table 1). Results of NGS had 100% concordance with 
pyrosequencing results for distinguishing wild-type and variant viruses by identifying mutations 
in the specific amino acid motifs in the neuraminidase gene as an indicator of antiviral resistance. 
NGS revealed low coverage sequence reads in negative specimens (10 reads each for PT-A-1 
and PT-A-4) revealing the need to establish a standard in which to confidently distinguish non­




NGS proficiency compared to pyrosequencing methodology for detecting antiviral resistance in influenza A virus
Two separate panels of proficiency specimens (A & B) were tested using NGS and compared to results obtained by laboratories performing 
pyrosequencing for currently circulating influenza A viruses. Known amino acid positions are unique to each type of neuraminidase gene (N1 or N2) 
separating out the viruses and varying the positions monitored for antiviral resistance.
Pyrosequencing NGS






H% Y% I% H% Y% I
PT-A-1 ND indeterminate -- -- -- -- -- -- 10 35.9% 1.3
PT-A-2 H1N1pdm09 H275 100 0 100 100 0 100 5728 99.6% 850
PT-A-3 H1N1pdm09 H275Y <10 >90 100 8 92 100 275 98.6% 38.3
PT-A-4 ND indeterminate 10 48.0% 1.6
PT-A-5 H1N1pdm09 H275Y 60-65 35-40 100 68 42 100 3165 99.8% 436
PT-A-6 H1N1pdm09 H275 100 0 100 100 0 100 2589 98.9% 361
PT-A-7 H1N1pdm09 H275 100 0 100 100 0 100 1364 99.1% 204
PT-A-8 H1N1pdm09 H275Y 60-65 35-40 100 59 41 100 3624 99.7% 497
PT-A-9 H1N1pdm09 H275Y 100 0 100 100 0 100 8878 99.6% 1427
PT-A-10 H1N1pdm09 H275, I223K 100 0 0 100 0 0 4924 99.6% 764
PT-B-1 Not tested H275 100 0 100 100 0 100 12,788 99.8% 639
PT-B-2 Not tested H275Y 0 100 100 0 100 100 8,031 99.9% 402
PT-B-3 Not tested H275, I223K 100 0 0 100 0 0 10,139 99.9% 508
PT-B-4 Not tested H275Y 60-65 35-40 100 60 40 100 11,496 99.9% 575
H3N2 E119 R292 N294 E119 R292 N294
PT-B-5 Not tested 100 100 100 100 100 100 8,059 99.9% 418
PT-B-6 Not tested E119V 0 (V100%) 100 100 0 (V100%) 100 100 12,878 99.9% 670
PT-B-7 Not tested R292K 100 0 (K100%) 100 100 0 (K100%) 100 30,550 99.9% 1,585
Non-specific viral sequencing reads in NGS data
Low coverage viral sequencing is an issue when working with clinical specimens. 
Collections from patients represent a wide array of pathogen quantities and qualities. Although 
sequencing is becoming more competitive with other conventional methodologies in terms of 
cost, there is a need for increasing sequencing depth in order to detect pathogenic viruses in 
clinical specimens. Deeper sequencing also allows for greater chance for detecting non-specific 
viral reads. For instance, other viruses were considered “poorly” detected by Pathseq™Virome 
in each clinical specimen; however, these results could not be substantiated by GSNAP 
alignments due to very few reads and coverages.
Like other clinical assays, NGS needs a cutoff to determine the true presence of a 
pathogen versus carry-over or contamination between specimens or other non-specific reads. 
True negative proficiency specimens (PT-A-1 and PT-A-4) contained 10 reads aligning to the 
H1N1 NA reference gene (false positive) whereas the human herpesvirus 5 that grew from a 
nasopharyngeal swab also only had 10 reads. Indeterminate results, such as these, may need to 
undergo repeat testing where more involved enrichment techniques can be employed to 
determine the true presence of a virus in low-titer clinical specimens.
Discussion:
We investigated applications of NGS in a clinical laboratory to detect pathogenic viruses 
in common specimen types and compared NGS data to that which is obtained by more 
conventional methods. In most cases, with the exception of one, information retrieved by NGS 
met or exceeded that of conventional methodologies. NGS proves to be a laboratory tool capable 
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of not only detecting pathogenic viruses in clinical specimens, but also predicting the effects of 
drug treatment as well.
Through increased use of NGS technologies, reference databases of whole genome 
sequences can grow and enhance a laboratory's ability to identify sequencing reads. NGS will 
change our approach as laboratorians and improve our ability to detect and more fully 
characterize agents of infectious disease in clinical specimens.
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Appendix C
Next generation sequencing in clinical virology diagnostics7
7 Original publication as cited: Parker J, Chen, J. Next generation sequencing in clinical virology diagnostics. 
Clinical Lab International, Feb/Mar 2017:6-9.
Abstract
Next generation sequencing (NGS) is a new technology that can be used for broad detection of 
infectious pathogens and is rapidly becoming an essential platform in clinical laboratories. It is 
not known how NGS will displace or enhance gold standard methodologies in infectious disease 
diagnosis at this time, but investigations have begun to understand its potential. Our objective 
was to investigate the feasibility and application of NGS technology in public health laboratories 
and compare NGS technology with conventional methods in terms of pathogenic virus detection.
Introduction
Methodologies to detect pathogenic viruses in clinical specimens have transitioned from classic 
cell culture and antibody-antigen techniques to more sensitive molecular methods such as 
polymerase chain reaction (PCR). The targeted nature of these methodologies inhibit their 
ability to accommodate the true diversity of human pathogens in a clinical specimen, especially 
viruses [1]. Next generation sequencing (NGS) technologies are quickly demonstrating their 
ability to provide broad detection of infectious agents in a target-independent manner [2-7]. 
NGS has many advantages beyond the improved detection of all suspected, unsuspected, or even 
novel pathogens in a clinical specimen [8]. Familiarization with pathogen genomic sequences 
within clinical specimens enhances our understanding of infectious disease through further 
discovery of pathogen variability and genotyping [9-11], drug resistance or response to therapy 
[12], vaccine development and efficacy monitoring [13], and further characterization of the 
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metagenome [14]. The use of NGS for routine use in clinical diagnostics is emerging with its 
own set of limitations and challenges [13, 15]. Focusing on viruses of public health importance, 
we compared the performance of NGS alongside other more common viral detection 
methodologies.
Conventional methods vs. NGS
We investigated applications of NGS in a clinical laboratory to detect pathogenic viruses in 
common specimen types and compared NGS data to that which could be obtained by more 
conventional methods for detecting and characterizing the following viruses of public health 
importance: adenovirus, herpesvirus, hepatitis C virus, and influenza [16]. We compared results 
obtained by NGS to viral culture, immunofluorescence staining, serum neutralization, and PCR 
in terms of turnaround time as well as the clinical relevance of the information obtained.
Table 1 describes the turnaround time of conventional methods to NGS for detecting 
adenoviruses and herpesviruses, both DNA viruses. The amount of time it takes to grow a virus 
in culture is variable, ranging from 1 day for herpes simplex viruses to 18 days for adenoviruses. 
All NGS data could be obtained in 4 days, which includes nucleic acid extraction, sequencing 
library preparation, sequencing, and data analysis. Although most laboratories are not currently 
equipped with in-house bioinformaticians, much of the analysis can be done simply using 
common sequencing analyzing software and the quickly growing number of applications online. 
For data analysis, we used PathSeq™Virome which enabled us to feed large read files into the 
application which would generate a report describing the viruses present, including a “detection 
score” to distinguish strong and weak presence. NGS data provided much more information 
regarding the exact isolate which may aid health professionals in tracking and relating individual 
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cases with others. Group C adenoviruses are treatable with cidofovir and NGS data was able to 
identify the amino acid motif that most affects antiviral resistance.
Hepatitis C virus (HCV) is a growing concern for public health and tends to be difficult to design 
targeted methodologies around due to the high variability of viral genomes known, even within 
the same patient. NGS is a powerful tool for characterizing HCV infections and, in our 
experience, more informational than targeted genotyping assays (Table 2). Since we were able 
to sequence nearly the entire HCV genome (coverage ranged from 92.4% - 95.6%), data could be 
generated describing the mutations at key locations across the genomes that are known to cause 
drug resistance. Antiviral resistance is also critical when characterizing current circulating 
influenza virus strains and NGS was able to identify viruses that would be considered susceptible 
to neuraminidase inhibitors (Table 3). In two cases, the viral load of the specimen was too low 
to achieve good genome coverage across the neuraminidase gene, but this issue could be 
resolved by screening specimens for high titer (i.e. qPCR) or utilizing enrichment techniques 
such as ultracentrifugation or filtration of other background nucleic acid.
In most cases, with the exception of one specimen that was unable to definitively identify 
a cytomegalovirus (HSV5, Table 1), information retrieved by NGS met or exceeded that of 
conventional methodologies. NGS proves to be a laboratory tool capable of not only detecting 
pathogenic viruses in clinical specimens, but also predicting the effects of drug treatment as well.
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Table C.1: Comparison of methods for detecting DNA viruses
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Specimen
Conventional Methodologies Next-generation sequencing
Viral Culture IFA
Serum 
Neutralization TAT PathSeq™Virome TAT








Nasal swab 4+ CPE on day 8 PositiveAdenovirus
Adenovirus
(type 3)
18 Human adenovirus B strainhuman/USA/UFL_Adv3a51/2007/3 4
Genital swab 3+ CPE on day 1 PositiveHSV1 Not performed 1 Human herpesvirus 1 strain H129 4
Genital swab 3+ CPE on day 1 PositiveHSV2 Not performed 1 Human herpesvirus 2 strain SD90e 4
NP Swab 1+ CPE on day 14 PositiveHSV5 Not performed 14
Torque Teno virus isolate US32 & 
Human herpesvirus 5 (trace) 4
TAT = turnaround time
Table C.2: NGS for characterizing hepatitis C viruses and potential resistance to infection inhibitors
Specimen PCR PathSeq™Virome







Serum Positive HCV Hepatitis C virus subtype 1a isolate BID V60 1 susceptible 2
Serum Positive HCV Hepatitis C virus subtype 1a isolate BID V179 susceptible susceptible 1
Serum Positive HCV
Hepatitis GB virus C genomic RNA for polyprotein 
isolate GT110;
Hepatitis C virus subtype 1a isoate BID V389
susceptible susceptible susceptible
Serum Positive HCV G virus strain HGV-lw isolate pHGVqz;Hepatitis C virus subtype 1a isolate BID V269 susceptible susceptible 1
Serum Positive HCV Hepatitis G virus isolate R10291;Hepatitis C virus subtype 1a isolate BID V173 susceptible susceptible 1
*Number of mutations within these particular genes that demonstrate resistance to various HCV antiviral therapies
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Table C.3: NGS for characterizing influenza viruses
Specimen NGS Neuraminidase Inhibitors - Drug Resistance Markers
NP swab Influenza A/H3 Amino acid positions: 110, 292, and 294 - Indeterminate
NP swab Influenza A/H3 Amino acid positions: 110, 292, and 294 - Susceptible (wild type)
NP swab Influenza A∕HINlpdm09 Amino acid positions: 223 and 275 - Susceptible (wild type)
NP swab Influenza B (Yamagata Lineage) Amino acid positions: 105, 117, 140, 197, 221, 273, 294 - Susceptible (wild type)
NP swab Influenza B (Yamagata Lineage) Amino acid positions: 105, 117, 140, 197, 221, 273, 294 - Susceptible (wild type)
NP swab Influenza B (Victoria Lineage) Amino acid positions: 105, 117, 140, 197, 221, 273, 294 - Susceptible (wild type)
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Summary
Through increased use of NGS technologies, reference databases of whole genome sequences 
can grow and enhance our ability to more definitively identify sequencing reads. Although this 
review describes conventional methods vs. NGS for detecting specific viruses, there was also 
evidence of the presence of co-infecting viruses such as hepatitis G and Torque Teno virus that 
weren't originally targeted. The standard 4 day turnaround time needed to complete NGS could 
be improved with extraction and library preparation automation, as well as advances in 
sequencing technology (each run ~40 hours). Based on our laboratory's experience and the 
growing body of literature, NGS will change our approach as clinical laboratorians and improve 
our ability to detect and more fully characterize agents of infectious disease in clinical specimens 
in a non-targeted manner.
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